

SUMMARY FOR DR. ANTHONY FAUCI FREEDOM OF INFORMATION ACT REQUESTS

Two FOIA Requests Outstanding And Subject To Litigation

January 28, 2021: FOIA #1 | FOIA Case #55847 (8)

We requested copies of Dr. Anthony Fauci's employment contracts, daily calendar, confidentiality and economic interest disclosure documents and a current job description.

May 21, 2021: Partial production at 4:13pm, Bordine to Andrzejewski (37-42)

Email, partial response letter, and 51 pages of production (64-116). Remaining records being reviewed. Case #55847

Production was very limited and included internal employment documents from years 2000 and 2004. Further documents produced included some financial disclosure forms from 2014; federal for 278e from 2019 (filed 5/2020) and financial statements and transaction histories from 2019. (64-116)

Not included was Dr. Fauci's current employment agreement including all addendums and modifications; current job description; and confidentiality and conflict of interest documents.

May 27, 2021: Freedom of Information Act (FOIA) #3 to Robin Schofield (50-51)

Dr. Anthony Fauci: FY2020 documents filed by May 2021: confidentiality agreements, conflict of interest documents, economic interest disclosure documents, OGE Form 278e and accompanying paperwork.

May 27, 2021: Automatic reply messages from Schofield and Marg Moore confirming receipt of FOIA request. (48-49)

June 11, 2021: Roger Bordine to Andrzejewski re: FOIA #3 (50-51)

Please be advised that your request is being aggregated under your existing NIH FOIA Case # 55847, as it seeks similar documents already requested.

June 11, 2021: Andrzejewski to Bordine (52-53) Case #55847

When will production on #55847 occur?

No response as of 09/13/2021

June 14, 2021: Request for Comment – Dr. Anthony Fauci (55-56)

Reached out to Dr. Fauci on his government email address (afauci@niaid.nih.gov) with a request for comment regarding his 400 media appearances during the pandemic. **Also, alerted Dr. Fauci to the FOIA request for his employment agreement and job description and the statutory law regarding non-production.** No response – only bounce back email which confirmed email receipt.

TIMELINE FOR DR. ANTHONY FAUCI FREEDOM OF INFORMATION ACT REQUESTS

January 22, 2021: (1)

Request for Comment to spokesperson at National Institute for Allergy and Infectious Diseases (NIAID) (email: naiaidnews@niaid.nih.gov regarding Dr. Anthony Fauci as the #1 most highly compensated federal employee (FY2019). No response.

January 24, 2021: (2)

2nd Request for Comment (see above) – No response.

January 25, 2021: Forbes column #1 (3-7)

Forbes, Dr. Anthony Fauci: The Highest Paid Employee In The entire U.S. Federal Government (766,139 views)

<https://www.forbes.com/sites/adamandrzejewski/2021/01/25/dr-anthony-fauci-the-highest-paid-employee-in-the-entire-us-federal-government/?sh=63455ef3386f>

January 28, 2021: FOIA #1 | FOIA Case #55847 (8)

We requested copies of Dr. Anthony Fauci's employment contracts, daily calendar, confidentiality and economic interest disclosure documents and a current job description.

January 28, 2021: FOIA #2 | FOIA Case #55819 (9)

We requested copies of statements from purchases by Dr. Anthony Fauci using p-card, credit cards, or any other electronic/credit means by Dr. Anthony Fauci during period 1/1/2020 through the current time.

January 28, 2021: Roger Bordine, Program Support, FOIA Office to Andrzejewski (10) Case #55847

Email to force use of online portal to submit FOIA #1, which we successfully re-filed using their portal.

January 28, 2021: Roger Bordine phone call to narrow request to Andrzejewski (11) Case #55847

It was reasonable to drop the daily calendar request/point, as Mr. Bordine said it would slow the process significantly. On the same day, I followed up with a confirmation email to Bordine dropping the daily calendar point.

January 28, 2021: Robin Schofield confirmation email establishing **Case #55819** to Andrzejewski (12-13) FOIA acknowledging email.

May 10, 2021: Andrzejewski email to Robin Schofield (14) Case #55819

What's the timeline for production?

May 10, 2021: Andrzejewski email to Roger Bordine (15-17) Case #55847

What's the timeline for production?

May 10, 2021: Final response letter Case #55819, Schofield to Andrzejewski (18-22)

Limited production and a closing of case from Robin Schofield. The production detailed January through

March 2020 electronic purchase records of transportation charges for Fauci via taxi, Uber, and other means. Three pages of production remitted.

May 18, 2021: Andrzejewski email to Robin Schofield (23) **Case #55819**
Why isn't there more production?

May 18, 2021: Andrzejewski email to Roger Bordine (24-26) **Case #55847**
2nd request – what's the production timeline?

May 18, 2021: Andrzejewski email to Roger Bordine (27-30) **Case #55847**
Please confirm that you are receiving these emails.

May 19, 2021: Schofield to Andrzejewski, **Case #55819** (31-32)
Confirmed with administrative office – no more documents.

May 20, 2021: Andrzejewski to Bordine (33-36) **Case #55847**
Deadline for production, or lawsuit: May 21 at 5pm ET.

May 21, 2021: Partial production at 4:13pm, Bordine to Andrzejewski (37-42)
Email, partial response letter, and 51 pages of production (64-116). Remaining records being reviewed.
Case #55847

Production was very limited and included internal employment documents from years 2000 and 2004. Further documents produced included some financial disclosure forms from 2014; federal for 278e from 2019 (filed 5/2020) and financial statements and transaction histories from 2019. (64-116)

Not included was Dr. Fauci's current employment agreement including all addendums and modifications; current job description; and confidentiality and conflict of interest documents.

May 27, 2021: Andrzejewski to Bordine (43-46) **Case #55847**
When will there be more production?

May 27, 2021: Freedom of Information Act (FOIA) #3 to Robin Schofield (50-51)
Dr. Anthony Fauci: FY2020 documents filed by May 2021: confidentiality agreements, conflict of interest documents, economic interest disclosure documents, OGE Form 278e and accompanying paperwork.

May 27, 2021: Automatic reply messages from Schofield and Marg Moore confirming receipt of FOIA request. (48-49)

June 11, 2021: Roger Bordine to Andrzejewski re: **FOIA #3** (50-51)
Please be advised that your request is being aggregated under your existing NIH **FOIA Case # 55847**, as it seeks similar documents already requested.

June 11, 2021: Andrzejewski to Bordine (52-53) **Case #55847**

When will production on #55847 occur? No response as of 09/13/2021

June 14, 2021: Request for Comment – Dr. Anthony Fauci (55-56)

Reached out to Dr. Fauci on his government email address (afauci@niaid.nih.gov) with a request for comment regarding his 400 media appearances during the pandemic. **Also, alerted Dr. Fauci to the FOIA request for his employment agreement and job description and the statutory law regarding non-production.** No response – only bounce back email which confirmed email receipt.

June 14, 2021: Request for Comment to NIAID spokesperson (54)

Reached out to agency spokespersons regarding Dr. Fauci media appearances during the pandemic. Because the job description for Dr. Fauci was never produced, our oversight was a lot weaker.

June 15, 2021: Forbes column #2 (59-63)

Forbes | Dr. Anthony Fauci's 400+ Media Events Cost Taxpayers During The Pandemic (10,833 views)
Is Dr. Fauci in violation of the Gillette Amendment? Bars the publicity man and a bureaucrat with propaganda. Again, production of job description and contract documents are material to this oversight inquiry. This shows harm from FOIA violations.

<https://www.forbes.com/sites/adamandrzejewski/2021/06/15/dr-anthony-faucis-400-media-events-cost-taxpayers-during-the-pandemic/?sh=7f05bc2912c3>

IMPORTANT -- FORBES REQUEST FOR COMMENT

Adam Andrzejewski <Adam@openthebooks.com>

Fri 1/22/2021 3:37 PM

To: niaidnews@niaid.nih.gov <niaidnews@niaid.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

To Whom It May Concern:

My name is Adam Andrzejewski, a senior policy contributor at *Forbes*. We are working on a factual piece finding that Dr. Anthony Fauci was the #1 most highly compensated federal employee last year, even out-earning President Donald Trump. **My deadline for comment is Sunday, January 24th at 5pm EST, 2pm PT.**

If you miss our deadline, we will do our best to update the piece after you respond. All compensation amounts referenced in the piece were captured via an open records request of the Office of Personnel Management (OPM).

Here's the first paragraph and topline where Dr. Anthony Fauci is mentioned in the piece:

Dr. Anthony Fauci makes more than every other employee in the entire federal government. In the latest year available, his 2019 salary of \$417,608, made him not only the highest paid doctor in the federal government, but the highest paid out of all four million federal employees.

In fact, Dr. Fauci even made more than the \$400,000 salary of the President of the United States.

Any context, feedback, or comment would be important to our readers at Forbes.

Sincerely,

Adam

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*

Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -

[Click here](#) and scroll down

Re: IMPORTANT -- FORBES REQUEST FOR COMMENT

Adam Andrzejewski <Adam@openthebooks.com>

Sun 1/24/2021 9:24 AM

To: niaidnews@niaid.nih.gov <niaidnews@niaid.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

2nd request for comment. Our deadline is tonight, Sunday, January 24th at 5pm ET and the piece will publish early on Monday morning. Having a comment or context from Dr. Fauci or NIAID is important to our readers at Forbes.

Please see below...

Adam

From: Adam Andrzejewski <Adam@openthebooks.com>

Sent: Friday, January 22, 2021 3:37 PM

To: niaidnews@niaid.nih.gov <niaidnews@niaid.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Subject: IMPORTANT -- FORBES REQUEST FOR COMMENT

To Whom It May Concern:

My name is Adam Andrzejewski, a senior policy contributor at *Forbes*. We are working on a factual piece finding that Dr. Anthony Fauci was the #1 most highly compensated federal employee last year, even out-earning President Donald Trump. **My deadline for comment is Sunday, January 24th at 5pm EST, 2pm PT.**

If you miss our deadline, we will do our best to update the piece after you respond. All compensation amounts referenced in the piece were captured via an open records request of the Office of Personnel Management (OPM).

Here's the first paragraph and topline where Dr. Anthony Fauci is mentioned in the piece:

Dr. Anthony Fauci makes more than every other employee in the entire federal government. In the latest year available, his 2019 salary of \$417,608, made him not only the highest paid doctor in the federal government, but the highest paid out of all four million federal employees.

In fact, Dr. Fauci even made more than the \$400,000 salary of the President of the United States.

Any context, feedback, or comment would be important to our readers at Forbes.

Sincerely,

Adam

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867



Jan 25, 2021, 07:00am EST | 766,077 views

Dr. Anthony Fauci: The Highest Paid Employee In The Entire U.S. Federal Government



Adam Andrzejewski Senior Contributor ⓘ
Policy

Listen to article 5 minutes



WASHINGTON, May 12, 2020 -- Anthony Fauci, director of the National Institute of Allergy and ... [+]
XINHUA NEWS AGENCY/GETTY IMAGES

Dr. Anthony Fauci made \$417,608 in 2019, the latest year for which federal salaries are available. That made him not only the highest paid doctor in the

federal government, but the highest paid out of all four million federal employees.

Sign Up for Topline: Be the first to get expert analysis as breaking news happens.

[Sign Up](#)

In fact, Dr. Fauci even made more than the \$400,000 salary of the President of the United States. All salary data was collected by OpenTheBooks.com via Freedom of Information Act requests.

Only federal employees whose salaries were funded by taxpayers were included in the study. Therefore, Tennessee Valley Authority CEO Jeffrey Lyash— whose salary is paid by revenues of the corporation (owned by the federal government) — was not included.

\$2.5 million. That's how much Dr. Fauci, Director of the National Institute for Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) and current Chief Medical Advisor to the President, will make in salary from 2019 through 2024, if he stays in his post through the end of the current Administration, and doesn't (or didn't already) get a raise.

In a ten-year period between 2010 and 2019, Fauci made \$3.6 million in salary. Since 2014, Fauci's pay [increased](#) from \$335,000 to the current \$417,608.

MORE FROM [FORBES ADVISOR](#)

Score 5% Back In Your Top Spending Category With New Citi Custom Cash Card

By **Robin Saks Frankel** Forbes Advisor Staff

December 2020 Stock Market Outlook

By **Anna-Louise Jackson** Contributor

In an August 13, 2020 [Instagram interview](#) with actor Matthew McConaughey, Dr. Fauci was asked (at point 16:49) if he had millions of dollars invested in the vaccines. Dr. Fauci laughed and answered, “Matthew, no, I got zero! I am a government worker. I have a government salary.” He didn’t mention his \$417,608 salary was the largest in the entire federal government.

Dr. Fauci became the early face of the White House Coronavirus Task Force, appearing daily, often in a live broadcast, to update the nation on the emerging COVID-19 disease. In March 2020, he convinced President Donald Trump on the 15-day lockdown policy to try and flatten the curve, and reportedly advocated on [March 29, 2020](#), for extending the policy beyond its initial 15 days.

Vice President Mike Pence, who chaired the Taskforce might have outranked Dr. Fauci in authority, but the VP’s \$235,100 salary in 2019, was less than the well-paid NIH director with whom he shared the stage.

Their Taskforce colleague Dr. Deborah Birx earned \$305,972 in 2019, also less than Dr. Fauci’s salary.

In comparison to Dr. Fauci: Speaker Nancy Pelosi will earn [\\$223,500 this year](#). U.S. Supreme Court Chief Justice John Roberts [will make](#) \$270,700, and Members in the House of Representatives and Senators [will make](#) \$174,000. Four-star military generals outrank, but still fall below Dr. Fauci at \$268,000 a year.

The Centers for Disease Control and Prevention (CDC) scientist Dr. Stephen Lindstrom in charge of overseeing the CDC COVID-19 testing system, a system whose [early roll-out failure](#) set the U.S. testing system back several crucial weeks, made \$108,747 in basic pay, an additional \$23,533 in adjusted pay, and received an “award” of \$750 in 2019.

The 80-year-old Dr. Fauci holds a medical degree from Cornell University and began his 53-year career at NIH in 1968. He assumed his NIAID Director position in 1984 and has advised every president since President Ronald Reagan, though he serves directly under the NIH Director Francis Collins. Known as the nation's top infectious disease expert, he qualifies for a full federal pension and social security under pre 1984 federal pension reform rules.

The Executive Branch [includes](#) 2.1 million federal agency employees, 1.4 million members of the military, and 500,000 postal employees. Federal employee salaries are generally capped at level [IV of the Executive Schedule](#), which was \$172,500 in 2019.

However, there are exceptions, as Dr. Fauci's salary demonstrates. The exception exists to make federal salaries for doctors and scientists more competitive with the private-sector.

In our data at [OpenTheBooks.com](#), there are three doctors, all working for HHS, who out-earn the U.S. President with 2019 incomes ranging from \$406,000 to \$417,000.

Critics and lifetime achievements

On October 19, 2020, President Trump called Dr. Fauci "[a disaster](#)," though his criticism appeared to be unrelated to the doctor's salary.

In 2008, President George W. Bush [honored](#) Dr. Anthony Fauci with the Presidential Medal of Freedom, the highest civilian honor.

Dr. Fauci is the 32nd-most highly cited living researcher according to an [analysis](#) of Google Scholar citations. Polling has shown he's [the most trusted](#) public figure in the U.S. for information on the pandemic and reliable information on Covid-19 vaccines.

Follow me on [Twitter](#) or [LinkedIn](#). Check out my [website](#) or some of my other work [here](#).



Adam Andrzejewski

Adam Andrzejewski (say: And-G-F-ski) is the CEO/Founder of OpenTheBooks.com. Mission: "Every Dime, Online, In Real Time." Last year we filed 40,000 FOIA requests and... **Read More**

Reprints & Permissions

ADVERTISEMENT

Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Adam Andrzejewski <Adam@openthebooks.com>

Thu 1/28/2021 2:23 PM

To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Dear Open Records Officer,

If you are not the right person, please forward this request to the proper FOIA officer.

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.
2. Daily calendar from 1/1/2019 to the present time.
3. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
4. Current job description.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes

Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -

[Click here](#) and scroll down

Dr. Anthony Fauci -- Freedom of Information Act (FOIA) request

Adam Andrzejewski <Adam@openthebooks.com>

Thu 1/28/2021 2:26 PM

To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Dear Open Records Officer,

If you are not the right person, please forward this request to the proper FOIA officer.

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. Copies of all statements from purchases by p-cards, credit cards, or any other electronic/credit means by Dr. Anthony Fauci during the period 1/1/2020 through the current time.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes

Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -

[Click here](#) and scroll down

RE: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

NIH FOIA <nihfoia@od.nih.gov>

Thu 1/28/2021 2:40 PM

To: Adam Andrzejewski <Adam@openthebooks.com>

Cc: NIH FOIA <nihfoia@od.nih.gov>

Good Afternoon,

Thank you for your email. The NIH FOIA Office accepts FOIA requests via the NIH FOIA Portal (PAL) found here:
<https://foiaportal.nih.gov/>

Please submit your request via the NIH FOIA Portal.

Thank you.

Roger Bordine

Program Support

Freedom of Information Office

National Institutes of Health

Building 31, Room 5B35

31 Center Drive

Bethesda, MD 20892

Phone: 301-496-5633

Fax: 301-402-4541

Roger.bordine@nih.gov



From: Adam Andrzejewski <Adam@openthebooks.com>

Sent: Thursday, January 28, 2021 3:23 PM

To: NIH FOIA <nihfoia@od.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Subject: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Open Records Officer,

If you are not the right person, please forward this request to the proper FOIA officer.

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.
2. Daily calendar from 1/1/2019 to the present time.
3. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
4. Current job description.

Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Adam Andrzejewski <Adam@openthebooks.com>

Thu 1/28/2021 4:11 PM

To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Dear Roger,

Thank you for your help this afternoon. After speaking with you on the phone, my request is narrowed to only these three areas:

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. **All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.**
- 2.
3. **Any confidentiality documents, conflict documents, and economic interest disclosure documents.**
4. **Current job description.**

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>

Sent: Thursday, January 28, 2021 2:23 PM

To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>



Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Freedom of Information Office
5601 Fishers Lane, Suite 6G50
Bethesda, Maryland 20892
Tel (301) 451-5109
Fax (301) 480-0904/ Email foia@niaid.nih.gov

National Institutes of Health
National Institute of Allergy
and Infectious Diseases
Bethesda, MD 20892

January 28, 2021

Adam Andrzejewski
CEO & Founder
OpenTheBooks.com
200 S. Frontage Road
Suite 106
Burr Ridge, IL 60527
Adam@openthebooks.com

Re: FOI Case No. 55819

Dear Mr. Andrzejewski:

This acknowledges your January 28, 2021 Freedom of Information Act (FOIA) request emailed to the National Institutes of Health (NIH) FOIA Office and forwarded to the National Institute of Allergy and Infectious Diseases (NIAID) FOIA Office the same day. You requested the following information:

1. Copies of all statements from purchases by p-cards, credit cards, or any other electronic/credit means by Dr. Anthony Fauci during the period 1/1/2020 through the current time.

We are searching the files of the Office of the Director, NIAID for records responsive to your request. If any documents responsive to your request are located, they will be reviewed for releasability, and all releasable information will be sent to you. We will do everything possible to comply with your request in a timely manner. Please feel free to contact me at 301-451-5109 or email me at foia@niaid.nih.gov for additional information or to inquire about the status of your request.

Provisions of the FOIA allow us to recover part of the cost of complying with your request. We shall charge you for records in accordance with the Department of Health and Human Services FOIA Regulations as they apply to news media requesters; i.e., you will be charged for duplication at 10-cents per page although the first 100 pages are free; there is no charge for search or review time. If there are any fees associated with processing this request, you will be sent an invoice with our final response. Because we are uncertain that any applicable fees will

Page 2 – Letter to Adam Andrezejewski
RE: FOI Case NO. 55819

exceed our minimum charge (\$25.00), we are not addressing your request for a fee waiver at this time. However, if we determine there will be fees associated with processing your request, we will contact you at that time.

At any time during the processing of your request, you may seek assistance from the NIAID FOIA Public Liaison:

NIAID FOIA Public Liaison
Margaret Moore
5601 Fishers Lane, Suite 6G51
Bethesda, MD 20892
301-451-5109 (phone)
301-480-0904 (fax)
Email: mm52s@nih.gov

Sincerely,

Robin L.
Schofield -S

Digitally signed by
Robin L. Schofield -S
Date: 2021.01.29
08:46:36 -05'00'

Robin L. Schofield
FOIA Coordinator
National Institute of Allergy and Infectious Diseases

Re: Acknowledgement of FOIA Request #55819

Adam Andrzejewski <Adam@openthebooks.com>

Mon 5/10/2021 12:31 PM

To: Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>

Hi Robin,

Just following up on the status of my request... what's the anticipated timeline for production?

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Sent: Friday, January 29, 2021 7:49 AM

To: Adam Andrzejewski <Adam@openthebooks.com>

Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>

Subject: Acknowledgement of FOIA Request #55819

Good morning Mr. Andrzejewski,

Attached please find our acknowledgement of your Freedom of Information Act request.

Regards,

Robin

Robin L. Schofield, MPS
FOIA Coordinator
National Institute of Allergy and Infectious Diseases
National Institutes of Health

5601 Fishers Lane, 6G59
Rockville, MD 20892-9807
Phone: (301) 451-5109
Voicemail: (240) 627-3728
e-Fax: (301) 480-2285
E-mail: robin.schofield@nih.gov

Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Adam Andrzejewski <Adam@openthebooks.com>

Mon 5/10/2021 12:33 PM

To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Hi Roger,

Just following up on the status of my request... what's the anticipated timeline for production? We had narrowed the request so production could commence on a timely basis.

Adam

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*

Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -

[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>

Sent: Thursday, January 28, 2021 4:11 PM

To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Roger,

Thank you for your help this afternoon. After speaking with you on the phone, my request is narrowed to only these three areas:

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. **All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.**
- 2.
3. **Any confidentiality documents, conflict documents, and economic interest disclosure documents.**
4. **Current job description.**

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the their public officials, of their rights and responsibilities, of news and current or passing and for articles of opinion or features of interest to the public. The principal purpose of this



request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, January 28, 2021 2:23 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Open Records Officer,

If you are not the right person, please forward this request to the proper FOIA officer.

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.
2. Daily calendar from 1/1/2019 to the present time.
3. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
4. Current job description.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527



Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*

Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -

[Click here](#) and scroll down



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Freedom of Information Office
5601 Fishers Lane, Suite 6G50
Bethesda, Maryland 20892
Tel (301) 451-5109
Fax (301) 480-0904/ Email foia@niaid.nih.gov

National Institutes of Health
National Institute of Allergy
and Infectious Diseases
Bethesda, MD 20892

May 10, 2021

Adam Andrzejewski
CEO & Founder
OpenTheBooks.com
200 S. Frontage Road
Suite 106
Burr Ridge, IL 60527
Adam@openthebooks.com

Re: FOI Case No. 55819

Dear Mr. Andrzejewski:

This is a final response to your January 28, 2021 Freedom of Information Act (FOIA) request emailed to the National Institutes of Health (NIH) FOIA Office and forwarded to the National Institute of Allergy and Infectious Diseases (NIAID) FOIA Office the same day. You requested the following information:

1. Copies of all statements from purchases by p-cards, credit cards, or any other electronic/credit means by Dr. Anthony Fauci during the period 1/1/2020 through the current time.

Staff in the Office of Administrative Services, Office of Director and Extramural Administration Branch, of the NIAID searched the electronic procurement systems for records responsive to your request. That search three pages responsive to your request. This includes a local travel voucher. We have redacted a home address, employee identification number and cell phone number. No other information has been removed from the attached pages.

If you are not satisfied with the processing and handling of this request, you may contact the NIAID FOIA Public Liaison:

NIAID FOIA Public Liaison
Margaret Moore
5601 Fishers Lane, Suite 6G51
Bethesda, MD 20892
301-451-5109 (phone)
301-480-0904 (fax)
Email: mm52s@nih.gov

Page 2 – Letter to Adam Andrzejewski
RE: FOI Case No. 55819

In certain circumstances provisions of the FOIA and Department of Health and Human Services FOIA Regulations allow us to recover part of the cost of responding to your request. Because no unusual circumstances apply to the processing of your request, there is no charge associated with our response.

Sincerely,

Robin L.
Schofield -S

Digitally signed by
Robin L. Schofield -S
Date: 2021.05.10
14:41:38 -04'00'

Robin L. Schofield
FOIA Coordinator
National Institute of Allergy and Infectious Diseases

Enclosures: 3 pages

Document Header Information

Document Local Voucher DocumentLOCALTRIP001GX1
 Type: Name:
 TA Number: TANUM0P1RJ Trip Local Vouchers for January 2020 - February 2020
 Name:
 TA Date: 03/16/20 Currency: USD
 Organization:HHSNM1000000CCurrent Paid
 Status:
 Purpose: DocumentAll of these local vouchers were for meetings regarding COVID-19 updates. 1) January 28, 2020 - Uber from home to National Press Club \$14.25 2) January 28, 2020 - Taxi from White House to home \$11.13 3) January 29, 2020 - Uber from Home to Hyatt Crystal City Hotel for ASM Lecture \$16.20 Taxi from Hyatt to NIH - \$59.10 4) January 30, 2020 - Uber from home to Fox Studios (400 N. Capitol Street, NW) \$15.37 Taxi from Fox Studios to Humphrey Building \$7.21 5) February 5, 2020 - Taxi from Capitol to NIH \$65.70 Uber from home to Capitol \$16.04 6) February 7, 2020 - Uber from home to NIH where car was left overnight due to late White House meeting. \$15.37 7) February 9, 2020 - Uber from home to Convention Center for the Governor's Conference \$14.07 Taxi from Convention Center to home \$20.24 8) February 12, 2020 - Uber from home to Rayburn House Office Building \$16.35 9) February 13, 2020 - Taxi from Roosevelt Room of the White House with the Chairs and Ranking Members to Alexandria. \$30.94 Uber from Alexandria to NIH \$29.47 10) February 17, 2020 - Uber from home to USA Today Headquarters \$21.59 Uber from USA Today to home \$20.45 11) February 18, 2020 - Taxi from Council on Foreign Relations (1777 F Street, NW) to NIH \$34.08 12) Uber from home to Senate to NIH \$18.78 Taxi from Senate to NIH - \$66.38 13) February 28, 2020 - Uber from home to Capitol - \$16.22 Taxi from Capitol to NIH \$63.44 14) February 29, 2020 - Uber from home to White House \$11.67 Taxi from White House to Home \$18.55
 Detail:

Type Code:

Traveler Profile

Name: FAUCI, ANTHONY S ID:
 TID: NIH001005123 Organization: HHSNM1000000C
 Title: Duty Station: Main Campus
 Security Cl: Card: No Advance
 Office Address: BLDG 31 ROOM NUMBER 7A03
, EMAIL: afauci@niaid.nih.gov
 Office Phone: 301 496 2263 Cell Phone:
 Home Address: Personal Info
 Alternate Address: Home Phone: Personal Info
 Alternate Phone:

Document Totals

Total Expenses:	598.04
Reimbursable Expenses:	591.24
Non-Reimbursable Expenses:	6.80
Advance Applied:	.00
Net to Traveler:	591.24
Net to Government:	6.80
Pay to Charge Card:	.00

Document Totals by Expense Category

Expense Category	Cost	Advance Amount
TAV EXP	6.80	.00
TAXI/PUBLIC TRANS	591.24	.00
Total Expenses:	598.04	.00

Trip 1 Details

Expenses

Trip#: 1	Total Non-Per Diem Expenses:	598.04	Total Per Diem Expenses:	.00
Date	Description	Category	Cost	Pay Method
01/28/2020	Taxi from home to National Press Club	TAXI/PUBLIC TRANS	14.25	PERSONAL
01/29/2020	Taxi from White House to home	TAXI/PUBLIC TRANS	11.13	PERSONAL
01/29/2020	Taxi from Home to Hyatt Crystal City Hotel for ASM Lecture	TAXI/PUBLIC TRANS	16.20	PERSONAL
01/30/2020	Taxi from Hyatt to NIH	TAXI/PUBLIC TRANS	59.10	PERSONAL



01/30/2020Taxi	TAXI/PUBLIC TRANS	15.37	PERSONAL
Comment: Uber from home to Fox Studios (400 N. Capitol Street, NW)			
01/30/2020Taxi	TAXI/PUBLIC TRANS	7.21	PERSONAL
Comment: Taxi from Fox Studios to Humphrey Building \$7.21			
02/05/2020Taxi	TAXI/PUBLIC TRANS	16.04	PERSONAL
Comment: Uber from home to Capitol \$16.04			
02/05/2020Taxi	TAXI/PUBLIC TRANS	65.70	PERSONAL
Comment: Taxi from Capitol to NIH			
02/07/2020Taxi	TAXI/PUBLIC TRANS	15.37	PERSONAL
Comment: Uber from home to NIH where car was left overnight due to late White House meeting.			
02/09/2020Taxi	TAXI/PUBLIC TRANS	14.07	PERSONAL
Comment: Uber from home to Convention Center.			
02/09/2020Taxi	TAXI/PUBLIC TRANS	20.24	PERSONAL
Comment: Taxi from Convention Center to home			
02/12/2020Taxi	TAXI/PUBLIC TRANS	16.35	PERSONAL
Comment: Uber from home to Rayburn House Office Building			
02/13/2020Taxi	TAXI/PUBLIC TRANS	30.94	PERSONAL
Comment: Taxi from Roosevelt Room of the White House with the Chairs and Ranking Members to Alexandria			
02/13/2020Taxi	TAXI/PUBLIC TRANS	29.47	PERSONAL
Comment: Uber from Alexandria to NIH			
02/17/2020Taxi	TAXI/PUBLIC TRANS	21.59	PERSONAL
Comment: Uber from home to USA Today interview about Coronavirus			
02/17/2020Taxi	TAXI/PUBLIC TRANS	20.45	PERSONAL
Comment: Uber home from USA Today studios after interview about Coronavirus			
02/18/2020Taxi	TAXI/PUBLIC TRANS	34.08	PERSONAL
Comment: Taxi from Council on Foreign Relations (1777 F Street, NW) to NIH			
02/25/2020Taxi	TAXI/PUBLIC TRANS	18.78	PERSONAL
Comment: Uber from home to Senate to NIH			
02/25/2020Taxi	TAXI/PUBLIC TRANS	66.38	PERSONAL
Comment: Taxi from Senate to NIH			
02/28/2020Taxi	TAXI/PUBLIC TRANS	16.22	PERSONAL
Comment: Uber from home to Capitol			
02/28/2020Taxi	TAXI/PUBLIC TRANS	58.33	PERSONAL
Comment: Taxi from Capitol to NIH			
02/29/2020Taxi	TAXI/PUBLIC TRANS	11.67	PERSONAL
Comment: Uber from home to White House			
02/29/2020Taxi	TAXI/PUBLIC TRANS	17.03	PERSONAL
Comment: Taxi from White House to Home			
03/16/2020Local Voucher Fee	TAV EXP	6.80	EFT

Account Summary for the Selected Trip

Org: HHSN	Label: Local	Acct Code: 8325887.2020.100/108202/D/21010 DOMESTIC-PROGRAM MEETING-OPERATIONAL/1/3210 /1263	598.04
Expense Category: TAV EXP	Fiscal Year: 2020	Amount: 6.80	
Expense Category: TAXI/PUBLIC TRANS	Fiscal Year: 2020	Amount: 591.24	
Total:			598.04

Payment Detail Information

Organization	Label	Accounting String	Payment Method	Amount
HHSN	Local Vouchers	8325887.2020.100/108202/D/21010 DOMESTIC-PROGRAM MEETING-OPERATIONAL/1/3210 /1263	EFT	6.80
HHSN	Local Vouchers	8325887.2020.100/108202/D/21010 DOMESTIC-PROGRAM MEETING-OPERATIONAL/1/3210 /1263	PERSONAL	591.24

Totals by Label

HHSN	Local Vouchers	8325887.2020.100/108202/D/21010 DOMESTIC-PROGRAM MEETING-OPERATIONAL/1/3210 /1263	598.04
Total			

Totals by Payment Method

EFT Total	6.80
PERSONAL	591.24
Total	

Attachments

Attachments Exist



Description

Cost

Document History 02/03/2021 Local Voucher: LOCALTRIP001GXI

Copyright 1989-2009 Concur Government Edition: Concur Inc. FAUCI, ANTHONY S. NIH001005123

STATUS	DATE	TIME	SIGNATURE NAME	REASON
CREATED	03/16/2020	1:50PMEST	ROBINSON, WHITNEY CHERELLE	
VOUCHER PREPARED	03/18/2020	10:01AMEST	ROBINSON, WHITNEY CHERELLE	
CERTIFIED	03/18/2020	10:04AMEST	FAUCI, ANTHONY Stephen	
ADJUSTED	03/18/2020	11:14AMEST	RUSHING, MELISSA JANE GASS	
ADJUSTED	03/20/2020	1:29PMEST	ROBINSON, WHITNEY CHERELLE	
ADJUSTED	03/25/2020	5:51AMEST	RUSHING, MELISSA JANE GASS	
ADJUSTED	03/25/2020	6:55AMEST	RUSHING, MELISSA JANE GASS	
ADJUSTED	03/25/2020	7:28AMEST	RUSHING, MELISSA JANE GASS	
REVIEWED	03/25/2020	7:29AMEST	RUSHING, MELISSA JANE GASS	
ADJUSTED	03/27/2020	10:00AMEST	ROBINSON, WHITNEY CHERELLE	
ADJUSTED	03/31/2020	7:22AMEST	ALSTON, MARC IANWAR	
ADJUSTED	04/15/2020	12:51PMEST	ALSTON, MARC IANWAR	
ADJUSTED	04/16/2020	6:40AMEST	ALSTON, MARC IANWAR	
APPROVED	04/16/2020	7:04AMEST	ALSTON, MARC IANWAR	
PENDING	04/16/2020	7:04AMEST	SYSUTILITY	
Paid	04/17/2020	4:00PMEST	User, EAI	

I certify that the electronic signatures listed above are valid and on file

SIGNED DATE

Document Signatures

Traveler/Preparer Name:	_____
Traveler/Preparer Signature:	_____
Date:	_____
Approver Name:	_____
Approver Signature:	_____
Date:	_____

Re: Final Response to FOIA Request No. 55819

Adam Andrzejewski <Adam@openthebooks.com>

Tue 5/18/2021 4:29 PM

To: Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>

Hi Robin,

Thank you for the production. These records detail the transactions through 3/15/2020... however, we requested the transactions from 1/2020 through 1/28/2021. Why isn't there production after 3/15/2020?

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Sent: Monday, May 10, 2021 1:45 PM

To: Adam Andrzejewski <Adam@openthebooks.com>

Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>

Subject: Final Response to FOIA Request No. 55819

Dear Mr. Andrzejewski:

Attached please find our final response to your FOIA request.

Regards,

Robin L. Schofield, MPS
FOIA Coordinator
National Institute of Allergy and Infectious Diseases
National Institutes of Health

5601 Fishers Lane, 6G59
Rockville, MD 20892-9807
Phone: (301) 451-5109
Voicemail: (240) 627-3728
e-Fax: (301) 480-2285
E-mail: robin.schofield@nih.gov

Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Adam Andrzejewski <Adam@openthebooks.com>

Tue 5/18/2021 4:35 PM

To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Hi Roger,

Please respond to this email... see below. We were good about narrowing our request back in January. Now, we are concerned about production -- on a timely basis. It's been nearly four months and the production is not complicated.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Monday, May 10, 2021 12:33 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

Just following up on the status of my request... what's the anticipated timeline for production? We had narrowed the request so production could commence on a timely basis.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, January 28, 2021 4:11 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>



Cc: Adam Andrzejewski <Adam@openthebooks.com>

Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Roger,

Thank you for your help this afternoon. After speaking with you on the phone, my request is narrowed to only these three areas:

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. **All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.**
- 2.
3. **Any confidentiality documents, conflict documents, and economic interest disclosure documents.**
4. **Current job description.**

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>

Sent: Thursday, January 28, 2021 2:23 PM

To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Subject: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Open Records Officer,



not the right person, please forward this request to the proper FOIA officer.

28

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.
2. Daily calendar from 1/1/2019 to the present time.
3. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
4. Current job description.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down

Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Adam Andrzejewski <Adam@openthebooks.com>

Tue 5/18/2021 4:51 PM

To: Roger.bordine@nih.gov <Roger.bordine@nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Hi Roger,

If you weren't getting these emails, I have a couple of requests for an ETA on my FOIA request. If you would be so kind, please let me know.

Thank you.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Tuesday, May 18, 2021 4:35 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

Please respond to this email... see below. We were good about narrowing our request back in January. Now, we are concerned about production -- on a timely basis. It's been nearly four months and the production is not complicated.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Friday, May 10, 2021 12:33 PM



To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

Just following up on the status of my request... what's the anticipated timeline for production? We had narrowed the request so production could commence on a timely basis.

Adam

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes

Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -

[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>

Sent: Thursday, January 28, 2021 4:11 PM

To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Roger,

Thank you for your help this afternoon. After speaking with you on the phone, my request is narrowed to only these three areas:

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. **All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.**
- 2.
3. **Any confidentiality documents, conflict documents, and economic interest disclosure documents.**
4. **Current job description.**

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the citizens of the general public and is not for the principal purpose of gaining personal or



Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, January 28, 2021 2:23 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Open Records Officer,

If you are not the right person, please forward this request to the proper FOIA officer.

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.
2. Daily calendar from 1/1/2019 to the present time.
3. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
4. Current job description.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at *Forbes*. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867



Policy Contributor | *Forbes*

Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down

RE: Final Response to FOIA Request No. 55819

Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Wed 5/19/2021 8:05 AM

To: Adam Andrzejewski <Adam@openthebooks.com>

Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>

Good morning Mr. Andrzejewski,

We have confirmed with our administrative offices that we have provided all of the documents responsive to your request.

Regards,

Robin L. Schofield, MPS

FOIA Coordinator

National Institute of Allergy and Infectious Diseases

From: Adam Andrzejewski <Adam@openthebooks.com>

Sent: Tuesday, May 18, 2021 5:30 PM

To: Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>

Subject: Re: Final Response to FOIA Request No. 55819

Hi Robin,

Thank you for the production. These records detail the transactions through 3/15/2020... however, we requested the transactions from 1/2020 through 1/28/2021. Why isn't there production after 3/15/2020?

Adam

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes

Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -

[Click here](#) and scroll down

From: Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Sent: Monday, May 10, 2021 1:45 PM

To: Adam Andrzejewski <Adam@openthebooks.com>

Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>

Subject: Final Response to FOIA Request No. 55819

Dear Mr. Andrzejewski:

Attached please find our final response to your FOIA request.



Regards,

Robin L. Schofield, MPS
FOIA Coordinator
National Institute of Allergy and Infectious Diseases
National Institutes of Health

5601 Fishers Lane, 6G59
Rockville, MD 20892-9807

Phone: (301) 451-5109

Voicemail: (240) 627-3728

e-Fax: (301) 480-2285

E-mail: robin.schofield@nih.gov

Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Adam Andrzejewski <Adam@openthebooks.com>

Thu 5/20/2021 11:32 AM

To: Roger.bordine@nih.gov <Roger.bordine@nih.gov>

Cc: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>

Hi Roger,

If I do not hear from you or NIH by tomorrow, Friday, May 21st at 5pm ET, then we will take our complaint to the next level. The third prong of our charitable mission is [inflection point lawsuits](#) and this FOIA request falls squarely under that vertical.

Please see the email chain forwarded below.

I am looking forward to an estimated time of arrival of production subject to my request. So, far the agency is in gross violation of FOIA statutes and deadlines. For example, you had 20 days to issue a determination and extension if necessary.

I'm giving you opportunity to cure the breaches in the law as soon as possible.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Tuesday, May 18, 2021 4:51 PM
To: Roger.bordine@nih.gov <Roger.bordine@nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

If you weren't getting these emails, I have a couple of requests for an ETA on my FOIA request. If you would be so kind, please let me know.

Thank you.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867



Senior Policy Contributor | Forbes



Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Tuesday, May 18, 2021 4:35 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

Please respond to this email... see below. We were good about narrowing our request back in January. Now, we are concerned about production -- on a timely basis. It's been nearly four months and the production is not complicated.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Monday, May 10, 2021 12:33 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

Just following up on the status of my request... what's the anticipated timeline for production? We had narrowed the request so production could commence on a timely basis.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, January 28, 2021 4:11 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Roger,

Thank you for your help this afternoon. After speaking with you on the phone, my request is narrowed to only these three areas:

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. **All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.**
- 2.
3. **Any confidentiality documents, conflict documents, and economic interest disclosure documents.**
4. **Current job description.**

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, January 28, 2021 2:23 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents



38

Dear Open Records Officer,

If you are not the right person, please forward this request to the proper FOIA officer.

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.
2. Daily calendar from 1/1/2019 to the present time.
3. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
4. Current job description.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down

NIH FOIA Request - 55847 Andrzejewski - Partial Response

NIH FOIA <nihfoia@od.nih.gov>

Fri 5/21/2021 4:13 PM

To: Adam Andrzejewski <Adam@openthebooks.com>

Cc: NIH FOIA <nihfoia@od.nih.gov>

📎 3 attachments (21 MB)

55847 Andrzejewski - Partial Response Letter.pdf; NIH FOIA - 55847 Andrzejewski - Partial Response - Employment Contract.pdf; Partial Response - NIH FOIA 55847 - Most Recent 278e.pdf;

Good Afternoon,

Please see the attached letter and records in response to your NIH FOIA request.

Thank you.

Roger Bordine

Program Support

Freedom of Information Office

National Institutes of Health

Building 31, Room 5B35

31 Center Drive

Bethesda, MD 20892

Phone: 301-496-5633

Fax: 301-402-4541

Roger.bordine@nih.gov



From: Adam Andrzejewski <Adam@openthebooks.com>

Sent: Tuesday, May 18, 2021 5:35 PM

To: NIH FOIA <nihfoia@od.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

Please respond to this email... see below. We were good about narrowing our request back in January. Now, we are concerned about production -- on a timely basis. It's been nearly four months and the production is not complicated.

Adam

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867



Senior Policy Contributor | Forbes

57

Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Monday, May 10, 2021 12:33 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

Just following up on the status of my request... what's the anticipated timeline for production? We had narrowed the request so production could commence on a timely basis.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, January 28, 2021 4:11 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Roger,

Thank you for your help this afternoon. After speaking with you on the phone, my request is narrowed to only these three areas:

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. **All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.**
- 2.
3. **Any confidentiality documents, conflict documents, and economic interest disclosure documents.**
4. **Current job description.**

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at *Forbes*. **Electronic copies are requested.** This is not a commercial request. **This is also a for fee waiver**, should any fees be imposed, as this information bears on the public



business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, January 28, 2021 2:23 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Open Records Officer,

If you are not the right person, please forward this request to the proper FOIA officer.

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.
2. Daily calendar from 1/1/2019 to the present time.
3. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
4. Current job description.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at *Forbes*. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.



Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Freedom of Information Office
Building 31, Room 5B-35
31 Center Drive, MSC 2107
Bethesda, Maryland 20892-2107
phone: (301) 496-5633
fax: (301) 402-4541

Via E-mail: Adam@openthebooks.com

May 21, 2021

Adam Andrzejewski
CEO & Founder
OpenTheBooks.com

Re: FOI Case No. 55847

Dear Mr. Andrzejewski:

This is a partial response to your January 28, 2021 Freedom of Information Act (FOIA) request addressed to the National Institutes of Health (NIH) FOIA Office and received in this office on the same day. You requested copies of the following related to Dr. Anthony Fauci:

1. All employment contracts, modifications and addendums since hiring as Director, National Institute of Allergy and Infectious Diseases.
2. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
3. Current job description.

Thus far, the NIH FOIA Office has completed review of 51 pages responsive to your request, and they are enclosed with this letter. The remaining records are still under the review process and once that review has concluded, a final response will be sent to you.

If you are not satisfied with the processing and handling of this request, you may contact the OD FOIA Public Liaison and/or the Office of Government Information Services (OGIS):

NIH FOIA Public Liaison

Denean Standing-Ojo
Public Affairs Specialist
Office of Communications and Public Liaison
Building 31, Room 5B52S
31 Center Drive
Bethesda, MD 20814
301-496-5077 (phone)
301-496-0818 (fax)
nihfoia@od.nih.gov (email)

OGIS

National Archives and Records Admin
8601 Adelphi Rd - OGIS
College Park, MD 20740-6001
202-741-5770 (phone)
1-877-684-6448 (toll-free)
202-741-5769 (fax)
ogis@nara.gov (email)



In certain circumstances, provisions of the FOIA and HHS FOIA Regulations allow us to recover part of the cost of responding to your request. Because no unusual circumstances apply to the processing of your request, there are no charges for search time.

If you have any questions about this response, please call the NIH FOIA office at 301-496-5633.

Sincerely,

Hawyee
Yan -S

Digitally signed by
Hawyee Yan -S
Date: 2021.05.21
16:45:50 -04'00'

Hawyee Yan
For
Gorka Garcia-Malene
Freedom of Information Officer, NIH

Attachments: 51 pages, 2 PDF's

Re: NIH FOIA Request - 55847 Andrzejewski - Partial Response

Adam Andrzejewski <Adam@openthebooks.com>

Thu 5/27/2021 2:09 PM

To: NIH FOIA <nihfoia@od.nih.gov>

Cc: Roger.bordine@nih.gov <Roger.bordine@nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>

Hi Roger,

The partial production last Friday was received. Thank you.

When do you expect to produce the remainder of responsive documents?

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -
[Click here](#) and scroll down

From: NIH FOIA <nihfoia@od.nih.gov>
Sent: Friday, May 21, 2021 4:12 PM
To: Adam Andrzejewski <Adam@openthebooks.com>
Cc: NIH FOIA <nihfoia@od.nih.gov>
Subject: NIH FOIA Request - 55847 Andrzejewski - Partial Response

Good Afternoon,
Please see the attached letter and records in response to your NIH FOIA request.

Thank you.

Roger Bordine
Program Support
Freedom of Information Office
National Institutes of Health
Building 31, Room 5B35
31 Center Drive
Bethesda, MD 20892

Phone: 301-496-5633
Fax: 301-402-4541
Roger.bordine@nih.gov



From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Tuesday, May 18, 2021 5:35 PM
To: NIH FOIA <nihfoia@od.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

Please respond to this email... see below. We were good about narrowing our request back in January. Now, we are concerned about production -- on a timely basis. It's been nearly four months and the production is not complicated.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Monday, May 10, 2021 12:33 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Hi Roger,

Just following up on the status of my request... what's the anticipated timeline for production? We had narrowed the request so production could commence on a timely basis.

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, January 28, 2021 4:11 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Re: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Roger,

Thank you for your help this afternoon. After speaking with you on the phone, my request is narrowed to only these three areas:

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

1. **All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.**
- 2.
3. **Any confidentiality documents, conflict documents, and economic interest disclosure documents.**
4. **Current job description.**

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -
[Click here](#) and scroll down

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, January 28, 2021 2:23 PM
To: nihfoia@mail.nih.gov <nihfoia@mail.nih.gov>
Cc: Adam Andrzejewski <Adam@openthebooks.com>
Subject: Freedom of Information Act (FOIA) request -- Dr. Anthony Fauci documents

Dear Open Records Officer,

If you are not the right person, please forward this request to the proper FOIA officer.
We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:



1. All employment contracts, modifications and addendums since hiring as Director of National Institute for Health, National Institute of Allergy and Infectious Diseases.
2. Daily calendar from 1/1/2019 to the present time.
3. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
4. Current job description.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -
[Click here](#) and scroll down

FOIA Request -- Andrzejewski, Sr. Policy Contributor Forbes

Adam Andrzejewski <Adam@openthebooks.com>

Thu 5/27/2021 2:54 PM

To: Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>

Bcc: Sheila Cole <Sheila.Cole@openthebooks.com>

Hi Robin,

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

Any confidentiality agreements, conflict of interest documents, and economic interest disclosure documents pertaining to calendar year 2020 to the present. These include but are not limited to the OGE Form 278e and accompanying paperwork filed for 2020 with a May 2021 deadline.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes

Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -

[Click here](#) and scroll down

Automatic reply: FOIA Request -- Andrzejewski, Sr. Policy Contributor Forbes

Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Thu 5/27/2021 2:54 PM

To: Adam Andrzejewski <Adam@openthebooks.com>

Thank you for contacting the Freedom of Information Act (FOIA) Office of the National Institute of Allergy and Infectious Diseases (NIAID). I am out of the office until Tuesday, June 1. If you need assistance prior to then, please email foia@niaid.nih.gov

Robin Schofield
NIAID FOIA Coordinator

Automatic reply: FOIA Request -- Andrzejewski, Sr. Policy Contributor Forbes

Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>

Thu 5/27/2021 2:59 PM

To: Adam Andrzejewski <Adam@openthebooks.com>

I am out of the office. I will respond to your email as soon as possible when I return to work on Tuesday, June 1. If you need immediate assistance with a FOIA matter please email foia@niaid.nih.gov.

Thank you.

Marg

Margaret Moore

NIAID FOIA Office

FW: FOIA Request -- Andrzejewski, Sr. Policy Contributor Forbes

NIH FOIA <nihfoia@od.nih.gov>

Fri 6/11/2021 10:00 AM

To: Adam Andrzejewski <Adam@openthebooks.com>

Cc: NIH FOIA <nihfoia@od.nih.gov>

Good Morning,

Please be advised that your request below is being aggregated under your existing NIH FOIA request, 55847, as it seeks similar documents already requested in 55847.

Thank you.

Roger Bordine

Program Support

Freedom of Information Office

National Institutes of Health

Building 31, Room 5B35

31 Center Drive

Bethesda, MD 20892

Phone: 301-496-5633

Fax: 301-402-4541

Roger.bordine@nih.gov



From: Adam Andrzejewski <Adam@openthebooks.com>

Sent: Thursday, May 27, 2021 3:54 PM

To: Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>

Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>

Subject: FOIA Request -- Andrzejewski, Sr. Policy Contributor Forbes

Hi Robin,

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

Any confidentiality agreements, conflict of interest documents, and economic interest disclosure documents pertaining to calendar year 2020 to the present. These include but are not limited to the OGE Form 278e and accompanying paperwork filed for 2020 with a May 2021 deadline.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public of the federal, state, and local governments and will be used to inform citizens of the



actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*
Read Adam's '*Latest*' & '*Most Popular*' editorials at *Forbes* -
[Click here](#) and scroll down

Re: FOIA Request -- Andrzejewski, Sr. Policy Contributor Forbes

Adam Andrzejewski <Adam@openthebooks.com>

Fri 6/11/2021 10:25 AM

To: NIH FOIA <nihfoia@od.nih.gov>

Cc: Roger.bordine@nih.gov <Roger.bordine@nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>

Hi Roger,

The original request 55847 was submitted in January 2021 and is currently past-due. If you can get the updated documents in the latest request along with the full production from 55847 in real time and without further delay or extension, then I agree with your aggregation.

I am media as a senior policy contributor at Forbes. Please process 55847 as soon as possible. What is the timeline for production?

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's '*Latest*' & '*Most Popular*' editorials at Forbes -
[Click here](#) and scroll down

From: NIH FOIA <nihfoia@od.nih.gov>

Sent: Friday, June 11, 2021 10:00 AM

To: Adam Andrzejewski <Adam@openthebooks.com>

Cc: NIH FOIA <nihfoia@od.nih.gov>

Subject: FW: FOIA Request -- Andrzejewski, Sr. Policy Contributor Forbes

Good Morning,

Please be advised that your request below is being aggregated under your existing NIH FOIA request, 55847, as it seeks similar documents already requested in 55847.

Thank you.

Roger Bordine
Program Support
Freedom of Information Office
National Institutes of Health
Building 31, Room 5B35
31 Center Drive
Bethesda, MD 20892

Phone: 301-496-5633

Fax: 301-402-4541

From: Adam Andrzejewski <Adam@openthebooks.com>
Sent: Thursday, May 27, 2021 3:54 PM
To: Schofield, Robin (NIH/NIAID) [E] <robin.schofield@nih.gov>
Cc: Moore, Marg (NIH/NIAID) [E] <mmoore@niaid.nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>
Subject: FOIA Request -- Andrzejewski, Sr. Policy Contributor Forbes

Hi Robin,

We request copies of the following documents in regard to Dr. Anthony Fauci -- we request rolling production as documents are identified as responsive:

Any confidentiality agreements, conflict of interest documents, and economic interest disclosure documents pertaining to calendar year 2020 to the present. These include but are not limited to the OGE Form 278e and accompanying paperwork filed for 2020 with a May 2021 deadline.

This request is on behalf of American Transparency, a non-profit, IRS recognized 501(c)3 charitable organization and myself, Adam Andrzejewski, as a journalist and senior contributor at Forbes. **Electronic copies are requested.** This is not a commercial request. **This is also a request for fee waiver**, should any fees be imposed, as this information bears on the public business of the federal, state, and local governments and will be used to inform citizens of the actions of their public officials, of their rights and responsibilities, of news and current or passing events, and for articles of opinion or features of interest to the public. The principal purpose of this request is to access and disseminate information regarding the health, safety and welfare of the legal rights of the general public and is not for the principal purpose of gaining personal or commercial benefit.

Adam Andrzejewski, 200 S. Frontage Road, Suite 106, Burr Ridge, IL 60527

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -
[Click here](#) and scroll down

Request for comment: Forbes column on Dr. Anthony Fauci

Adam Andrzejewski <Adam@openthebooks.com>

Mon 6/14/2021 2:35 PM

To: niaidnews@niaid.nih.gov <niaidnews@niaid.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Bcc: Kirk Allen <Kirk@illinoisleaks.com>

To Whom It May Concern:

My name is Adam Andrzejewski, I'm a Forbes Senior Policy Contributor and writing a piece on the hundreds of media appearances of Dr. Anthony Fauci since the start of the pandemic.

This is a request for comment, context, or feedback. Your response is important to our readers at Forbes and we want your perspective.

Is press availability and/or public affairs duties material to Dr. Anthony Fauci's employment agreement or job description with the National Institute of Allergy and Infectious Diseases?

Under what authorization did Dr. Anthony Fauci become the primary public affairs contact at NIAID?

How many NIAID public affairs officers are employed?

The deadline on our request for comment is today, June 14 at 10 PM ET.

If you miss our deadline, we will do our best to update the piece when you respond.

Any context, feedback, or comment would be important to our readers at Forbes.

Sincerely,

Adam

Adam Andrzejewski (say: Angie-eff-ski)

CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | *Forbes*

Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -

[Click here](#) and scroll down

Fw: Request for comment: Forbes column on Dr. Anthony Fauci

Adam Andrzejewski <Adam@openthebooks.com>

Mon 6/14/2021 2:46 PM

To: afauci@niaid.nih.gov <afauci@niaid.nih.gov>

Cc: faucia@niaid.nih.gov <faucia@niaid.nih.gov>; Adam Andrzejewski <Adam@openthebooks.com>; niaidnews@niaid.nih.gov <niaidnews@niaid.nih.gov>

Dear Dr. Anthony Fauci,

My name is Adam Andrzejewski, I'm a Forbes Senior Policy Contributor and writing a piece on your media appearances since the start of the pandemic.

This is a request for comment, context, or feedback. Your response is important to our readers at Forbes and we want your perspective.

Is press availability and/or public affairs duties material to your employment agreement or job description with the National Institute of Allergy and Infectious Diseases? (Are you aware that my Freedom of Information Act request for your employment agreement and job description was filed in January 2020 and is still outstanding? As the director of NIAID, you should know that your agency is breaking federal FOIA law with non-production and lack of statutory responses. This harms journalism and I ask for your help in this matter.)

What do you say to the critics that say that you did so much media that you didn't have time to "follow the science"?

The Gillett Amendment limits the role of government officials and public relations. Did you ever have a legal opinion on the Gillett Amendment and your role in a public affairs capacity at NIAID?

The deadline on our request for comment is today, June 14 at 10 PM ET.

If you miss our deadline, we will do our best to update the piece when you respond.

Any context, feedback, or comment would be important to our readers at Forbes.

Sincerely,

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867

Senior Policy Contributor | Forbes
Read Adam's 'Latest' & 'Most Popular' editorials at Forbes -
[Click here](#) and scroll down

RE: Request for comment: Forbes column on Dr. Anthony Fauci

Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>

Mon 6/14/2021 2:47 PM

To: Adam Andrzejewski <Adam@openthebooks.com>

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

Request for comment: Forbes column on Dr. Anthony Fauci

Adam Andrzejewski <Adam@openthebooks.com>

Mon 6/14/2021 2:35 PM

To: niaidnews@niaid.nih.gov <niaidnews@niaid.nih.gov>

Cc: Adam Andrzejewski <Adam@openthebooks.com>

Bcc: Kirk Allen <Kirk@illinoisleaks.com>

To Whom It May Concern:

My name is Adam Andrzejewski, I'm a Forbes Senior Policy Contributor and writing a piece on the hundreds of media appearances of Dr. Anthony Fauci since the start of the pandemic.

This is a request for comment, context, or feedback. Your response is important to our readers at Forbes and we want your perspective.

Is press availability and/or public affairs duties material to Dr. Anthony Fauci's employment agreement or job description with the National Institute of Allergy and Infectious Diseases?

Under what authorization did Dr. Anthony Fauci become the primary public affairs contact at NIAID?

How many NIAID public affairs officers are employed?

The deadline on our request for comment is today, June 14 at 10 PM ET.

If you miss our deadline, we will do our best to update the piece when you respond.

Any context, feedback, or comment would be important to our readers at Forbes.

Sincerely,

Adam

Adam Andrzejewski (say: Angie-eff-ski)
CEO & Founder | OpenTheBooks.com | 312.320.1867


Senior Policy Contributor | *Forbes*
Read Adam's 'Latest' & 'Most Popular' editorials at *Forbes* -
[Click here](#) and scroll down



Jun 15, 2021, 07:58am EDT | 10,833 views

Dr. Anthony Fauci's 400+ Media Events Cost Taxpayers During The Pandemic



Adam Andrzejewski Senior Contributor 
Policy

Listen to article 5 minutes



WASHINGTON, DC - MARCH 12: National Institute Of Allergy And Infectious Diseases Director Anthony ... [\[+\]](#) GETTY IMAGES

New information has emerged casting doubt about whether Dr. Anthony Fauci has been serving the public interest or his own personal interests since

the Covid-19 pandemic began.

When did the doctor have time to follow the science?

Since January 1, 2020, Dr. Fauci participated in 354 television, radio, podcast, and online interviews, including lectures, panel discussions, speeches, and press conferences. Our auditors at OpenTheBooks.com compiled a database from the [online archive](#) posted at the National Institutes of Allergy and Infectious Diseases (NIAID).

Not included in the government's media disclosures were 1) Dr. Fauci's book deal and forthcoming [documentary](#) film with National Geographic, 2) many of the early pandemic press conferences with Donald Trump, and 3) the current twice-per-week conferences with Joe Biden's Covid-19 task force.

Taxpayers paid a hefty sum for Dr. Fauci's media appearances.

In January, our investigation [published](#) at Forbes found Dr. Fauci's salary in 2019 was \$417,608. In 2020, Dr. Fauci earned \$434,000 with estimated earnings of \$650,000 since the pandemic hit. Dr. Fauci out-earned all 4.3 million federal employees, including four-star generals and the president.

Critics have questioned why Dr. Fauci participated in so many interviews for such a long time when his position did not primarily involve public affairs.

Since 1913, the Gillett Amendment expressly limits the government's interaction with the public by [barring](#) the "publicity man" or "propagandist," i.e. taxpayer dollars must be used to inform the public, and not to manufacture public opinion. "Appropriated funds may not be used to pay a publicity expert unless specifically appropriated for that purpose," the law states.

MORE FROM [FORBES ADVISOR](#)

Score 5% Back In Your Top Spending Category With



by Citi Custom Cash Card



Why Your IRS Refund Is Late This Year

By **Ellen Chang** Contributor

Did Dr. Fauci blur the lines between publicity, propaganda, public affairs, and his positions as the Director of the National Institute of Allergy and Infectious Diseases and the Chief Medical Advisor to the President?

It's unclear why Dr. Fauci needed to go on a media tour when federal health agencies already employ public relations experts. We [reached out](#) to Dr. Fauci for comment and will update the piece if he responds.

In fact, the three agencies involved in pandemic response—National Institutes of Health (NIH), Centers For Disease Control (CDC), and the Food And Drug Administration (FDA)—already employ 162 public affairs officers for \$20 million in yearly payroll costs. On average, each public affairs officer earned \$128,000 in salary alone.

Here are the salary costs broken out by agency for their public affairs officer positions:

- NIH employed 80 public affairs officers for \$10.3 million.
- CDC employed 35 public affairs officers for \$4.6 million.
- FDA employed 46 public affairs officers for \$5.6 million.

Roughly \$30 million in cash compensation has already been paid out by these three agencies to public affairs officers since the pandemic became known (January 1, 2020 through the current date).

Dr. Fauci, however, has taken the lead role in pandemic-related public outreach efforts for the last 18 months. American taxpayers might wonder

why they're footing the bill for Dr. Fauci's salary when they're already paying for a small army of public affairs professionals.

Furthermore, since the release of Dr. Fauci's emails by The Washington Post and BuzzFeed, material questions have emerged as to whether the doctor misled the public during his media interviews.

Last week, National Geographic, Amazon AMZN -0.3%, and other booksellers [removed](#) a pre-sale option to purchase Dr. Fauci's book from their websites after his contradictory emails became public.

For example, a National Geographic interview with Dr. Fauci from May 2020 is [still posted](#) on the outlet's website entitled, "No Scientific Evidence The Coronavirus Was Made In A Chinese Lab." However, Dr. Fauci [recently admitted](#) further investigation is necessary and his emails show he was [alerted](#) to the lab-leak theory as early as February 2020.

According to *The New York Times* NYT -1.5%, Fauci is not [receiving royalties or payments](#) from the book or documentary with National Geographic.

Further Reading

Dr. Anthony Fauci media database at the National Institute of Allergy and Infectious Diseases, [here](#).

Dr. Anthony Fauci Is The Highest Paid Public Employee In The Entire Federal Government, [here](#).

A Call To Repeal The Gillett Amendment, [here](#).

National Geographic, No Scientific Evidence The Coronavirus Was Made In A Chinese Lab, [here](#).

NOTE: Our auditors at OpenTheBooks.com filed a Freedom of Information Act (FOIA) request for Anthony Fauci's employment contract (and other job

related documents) in January 2021. Despite repeated attempts, we have yet to receive production.

We [contacted Dr. Fauci directly](#) with our request for comment, as well as, the media contacts at NIAID. As of press time, no responses were forthcoming.

Follow me on [Twitter](#) or [LinkedIn](#). Check out my [website](#) or some of my other work [here](#).



Adam Andrzejewski

Adam Andrzejewski (say: And-G-F-ski) is the CEO/Founder of OpenTheBooks.com. Mission: "Every Dime, Online, In Real Time." Last year we filed 40,000 FOIA requests and... **Read More**

Reprints & Permissions

ADVERTISEMENT



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Freedom of Information Office
Building 31, Room 5B-35
31 Center Drive, MSC 2107
Bethesda, Maryland 20892-2107
phone: (301) 496-5633
fax: (301) 402-4541

Via E-mail: Adam@openthebooks.com

May 21, 2021

Adam Andrzejewski
CEO & Founder
OpenTheBooks.com

Re: FOI Case No. 55847

Dear Mr. Andrzejewski:

This is a partial response to your January 28, 2021 Freedom of Information Act (FOIA) request addressed to the National Institutes of Health (NIH) FOIA Office and received in this office on the same day. You requested copies of the following related to Dr. Anthony Fauci:

1. All employment contracts, modifications and addendums since hiring as Director, National Institute of Allergy and Infectious Diseases.
2. Any confidentiality documents, conflict documents, and economic interest disclosure documents.
3. Current job description.

Thus far, the NIH FOIA Office has completed review of 51 pages responsive to your request, and they are enclosed with this letter. The remaining records are still under the review process and once that review has concluded, a final response will be sent to you.

If you are not satisfied with the processing and handling of this request, you may contact the OD FOIA Public Liaison and/or the Office of Government Information Services (OGIS):

NIH FOIA Public Liaison

Denean Standing-Ojo
Public Affairs Specialist
Office of Communications and Public Liaison
Building 31, Room 5B52S
31 Center Drive
Bethesda, MD 20814
301-496-5077 (phone)
301-496-0818 (fax)
nihfoia@od.nih.gov (email)

OGIS

National Archives and Records Admin
8601 Adelphi Rd - OGIS
College Park, MD 20740-6001
202-741-5770 (phone)
1-877-684-6448 (toll-free)
202-741-5769 (fax)
ogis@nara.gov (email)



64

In certain circumstances, provisions of the FOIA and HHS FOIA Regulations allow us to recover part of the cost of responding to your request. Because no unusual circumstances apply to the processing of your request, there are no charges for search time.

If you have any questions about this response, please call the NIH FOIA office at 301-496-5633.

Sincerely,

Hawyee
Yan -S

Digitally signed by
Hawyee Yan -S
Date: 2021.05.21
16:45:50 -04'00'

Hawyee Yan

For

Gorka Garcia-Malene

Freedom of Information Officer, NIH

Attachments: 51 pages, 2 PDF's



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Bethesda, Maryland 20892

DEC 15 2004

TO: Elias Zerhouni, M.D.
Director, NIH

FROM: Deputy Director, NIH

SUBJECT: Recommendation for Pay Adjustment for Dr. Anthony S. Fauci

This is to request that the current retention allowance (b) (6) for Dr. Anthony S. Fauci be converted to a permanent pay adjustment in the amount (b) (6) over his base pay of (b) (6) in order to appropriately compensate him for the level of responsibility in his current position of Director, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), especially as it relates to his work on biodefense research activities. Dr. Fauci has received a retention allowance for the past three years to compensate for and retain his services. He continues to be routinely sought by academia and private industry for positions with compensation in excess (b) (6) per year. The continuation of outside offers at compensation levels well above his current salary of (b) (6) is evidence of his standing and stature throughout the Country. While these outside offers have been in key positions of prominence, none reflect the level of responsibility and influence on national health policy found in his current position of Director, NIAID. This pay adjustment would begin to close the gap in compensation between his current position and comparable positions in private industry.

Dr. Fauci, as Director, NIAID, is responsible for directing and managing the NIAID and serves as principal advisor to the Director, NIH, concerning research activities related to the diagnosis, treatment, and prevention of infectious diseases, asthma, and other allergic and immunologic diseases and to the critical field of biodefense research. He leads the Institute's intramural research program of basic and clinical research in allergic, infectious, and immunological diseases and manages the extramural programs conducted through research projects. He is responsible for managing a budget of over \$4 billion and a staff of over 1500 full-time employees.

Dr. Fauci was one of the first investigators to confront AIDS in the laboratory and the clinic, and as Director of the NIAID he also has the reputation as the Government's architect of AIDS research, as a world renowned scientist in AIDS research, and as advisor to the President and



66
638

congressional staff. His scientific expertise, together with his broad vision of research and public health needs and his superb ability to articulate complex scientific and ethical issues to the scientific community and public, have made him one of the Nation's most influential leaders in shaping this Country's response to the AIDS epidemic.

More recently, Dr. Fauci has been a key figure in the White House and Department's response to bioterrorism. His contributions to this effort have been outstanding and include the development of the departmental strategy to augment smallpox vaccine supplies and the development of a plan to develop new anthrax vaccine. He serves as an expert consultant to the White House, the Secretary of DHHS, congressional staff, and a number of HHS groups on the development of biodefense-related research and public health priorities. He is leading the development of a series of research initiatives, has coordinated fast-track initiatives for academia and industry participation in biodefense-related research, and is responsible for the development of future intermediate and long-range research plans and policies for a sustained and committed biomedical research response to bioterrorism threats. During FY 2004, under Dr. Fauci's leadership, NIAID significantly expanded, intensified, and accelerated its research programs in biodefense. Over 50 biodefense research initiatives in areas ranging from the basic biology of microbes and their interactions with the human immune system to preclinical and clinical evaluation of new therapeutics and vaccines have been launched or expanded. He was instrumental in developing the Regional and National Biocontainment Program, a new initiative to build biocontainment facilities and improve the Nation's response to bioterrorism attacks. NIAID awarded funding for the construction of two National Biocontainment Laboratories and nine Regional Biocontainment Laboratories, which will complement and support the research activities of NIAID's Regional Centers of Excellence for Biodefense and Emerging Infectious Disease Research. Three new intramural research facilities are in development to provide laboratory and vivarium facilities in support of the biodefense research effort as well. Dr. Fauci was instrumental in working with the Department, the White House, and the Congress in the development of the BioShield legislation – a landmark piece of legislation designed to expedite the conduct of research and development of medical countermeasures; has been actively involved in support of the Global Fund to Fight AIDS, Tuberculosis and Malaria and the development of the President's Emergency Plan for AIDS Relief (PEPFAR); and quickly initiated a program to develop medical countermeasures against nuclear/radiological and chemical weapons. In a remarkably short period of time, Dr. Fauci has made significant scientific advances to address agents of possible bioterrorism including anthrax, smallpox, and ebola and has made great strides in planning and completing vaccine trials. Most recently, he has been a key spokesperson on the flu vaccine shortage and has been instrumental in working with the Department on alternative solutions and policies.

Dr. Fauci is a member of the National Academy of Sciences, the Institute of Medicine of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Philosophical Society, the Royal Danish Academy of Science and Letters, and the European Academy of Sciences, as well as a number of other professional societies including the American College of Physicians, the American Society for Clinical Investigation, the Association of American Physicians, the Infectious Diseases Society of America, and the American Association of Immunologists. He has received numerous honorary Doctorate of Science degrees from

universities throughout the Country and the world. He serves on editorial boards of several scientific journals; as associate editor [REDACTED] (b) (6) as an editor of Harrison's Principles of Internal Medicine, the most widely used textbook of medicine in the world; and as author, coauthor, or editor of more than 1000 scientific publications, including several textbooks, making him one of the most prolific scientific authors in the Country and the world. In addition, Dr. Fauci has been the recipient of a large number of prestigious national and international awards for science and medicine.

Dr. Fauci's position continues to expand with the emergence of new and re-emerging infectious diseases (such as SARS, West Nile and pandemic flu) and with changes in our global environment, including threats of bioterrorism and global health concerns. The NIAID budget has doubled within the past several years. In addition, numerous new and expanded areas of focus, such as the biodefense initiative, coordination of the new NIH nuclear/radiation defense research program, coordination of the new NIH chemical defense research program, increased efforts in AIDS vaccine development, and the launching of an aggressive international clinical trials program, have significantly influenced the level of responsibility found in this position. I, therefore, request your favorable consideration of this pay adjustment to appropriately reflect the level of responsibility reflected in Dr. Fauci's position and to compensate him for his continued (b) (6) service at the NIH.

[REDACTED]
Raynard S. Kington, M.D., Ph.D.

DECISION:

(b) (6)

Approved

Disapproved

(b) (6)

Elias A. Zerhouni, M.D.
Director, NIH

1/7/04
Date

TITLE 42 VOLUNTARY CONVERSION STATEMENT

I, Anthony Fauci, M.D., voluntarily accept conversion from my current career Senior Executive Service appointment as Director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, to the same position under 42 U.S.C. Section 209 (f) at an annual salary (b) (6) effective January 16, 2000. I understand that any Physicians Comparability Allowance and/or retention allowances I have been receiving will terminate upon conversion to the Title 42 excepted service appointment.

In accepting this appointment, I understand that I will not be assigned to a classified position description and will no longer be subject to SES performance management provisions, including eligibility for SES performance awards (bonus and Presidential Rank Awards). I understand that my new appointment has a maximum annual leave carry-over ceiling of 240 hours but that I may retain any personal leave ceiling in excess of that amount to which I was entitled as an SES member.

As a Title 42 employee, I understand that I will no longer have many of the rights extended to me as an employee under the Senior Executive Service. Rights that I will forfeit include: appeal rights to actions such as termination for cause (e.g., personal or scientific misconduct or lack of performance, or administrative reasons), discharge, reduction in force, reduction in pay, and furlough. I further understand that any increase in pay, based on merit or an across-the-board comparability increase, is subject to approval by the Director, NIH.

Under the Title 42 appointment, I understand that I will continue to be subject to the Federal laws, regulations and benefits pertaining to: Federal Employees Retirement System or Civil Service Retirement System, FICA, Medicare, Federal Employees Group Life Insurance and Health Benefits, Annual and Sick Leave (same as Title 5 employees), training and professional development opportunities sponsored by the NIH, Occupational Medical Service Facilities, Workers Compensation, Withholding Taxes, Medical Qualifications, the DHHS Standards of Conduct (including conflict of interest and outside activities), Restrictions on Political Activity, and Tort Claims.

(b) (6)

Signature

01/05/00
Date

NOTIFICATION OF PERSONNEL ACTION

1. Name (Last, First, Middle) FAUCI	2. Social Security Number ANTHONY S	3. Date of Birth (b) (6)	4. Effective Date 01-30-00
---	---	------------------------------------	--------------------------------------

FIRST ACTION SECOND ACTION

(b) (6) 8-A. Code		6-B. Nature of Action	
6-C. Code		6-D. Legal Authority	
6-E. Code		6-F. Legal Authority	

7. FROM: Position Title and Number DIRECTOR NIAID	15. TO: Position Title and Number DIRECTOR NIAID
---	--

(b) (6)	(b) (6)
---------	---------

14. Name and Location of Position's Organization PHS, NATIONAL INSTITUTES OF HEALTH, NATL INST ALLERGY & INFECTIOUS DISEASES OFC DIR HNM1	22. Name and Location of Position's Organization PHS, NATIONAL INSTITUTES OF HEALTH, NATL INST ALLERGY & INFECTIOUS DISEASES OFC DIR HNM1
---	---

EMPLOYEE DATA

(b) (6)

POSITION DATA

(b) (6)

39. Duty Station Code (b) (6)	39. Duty Station (City - County - State or Overseas Location) BETHESDA MARYLAND
---	---

40. AGENCY DATA 41	42	43	44
------------------------------	-----------	-----------	-----------

45. Remarks (b) (6)

(b) (6)

46. Employing Department or Agency DEPARTMENT OF HEALTH AND HUMAN SERVICES	50. Signature/Authentication and Title of Approving Official (b) (6) APPOINTING OFFICER
--	---

47. Agency Code OPEN THE BOOKS	48. Personnel Office ID (b) (6)	49. Approval Date 01-28-00
--	---	--------------------------------------

PRIVACY ACT AND PUBLIC BURDEN STATEMENT

The Office of Personnel Management is authorized to request this information under sections 1362, 3301, 3364, and 3716 of title 5 of the US Code. Section 1104 of title 5 allows the Office of Personnel Management to delegate personnel management functions to other Federal agencies. If necessary, and usually in conjunction with another form or forms, this form may be used in conducting an investigation to determine your suitability or your ability to hold a security clearance, and it may be disclosed to authorized officials making similar, subsequent determinations.

Public burden reporting for this collection of information is estimated to vary from 5 to 30 minutes with an average of 15 minutes per response, including time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of the collection of information, including suggestions for reducing this burden, to Reports and Forms Management Officer, US Office of Personnel Management, 1900 E Street, NW, Washington, DC 20415.

ROUTINE USES Any disclosure of this record or information in this record is in accordance with routine uses found in System Notice OPM/GOVT-1, General Personnel Records. This system allows disclosure of information to training facilities, organizations deciding claims for retirement, insurance, unemployment, or health benefits, officials in litigation or administrative proceeding where the Government is a party, law enforcement agencies concerning a violation of law or regulation, Federal agencies for statistical reports and studies, officials of labor organizations recognized by law in connection with representing employees, Federal agencies or other sources requesting information for Federal agencies in connection with hiring or retaining, security clearance, security or suitability investigations, classifying jobs, contracting, or issuing licenses, grants, or other benefits, public and private organizations, including news media, which grant or publicize employee recognition and awards, the Merit Systems Protection Board, the Office of Special Counsel, the Equal Employment Opportunity Commission, the Federal

Labor Relations Authority, the National Archives, the Federal Acquisition Institute, and Congressional offices in connection with their official functions, prospective non-Federal employers concerning terms of employment, civil service status, length of service, and the date and nature of action for separation as shown on the SF 50 (or authorized exception) of a specifically identified individual, requesting organizations or individuals concerning the home address and other relevant information on those who might have contracted an illness or been exposed to a health hazard, authorized Federal and non-Federal agencies for use in computer matching, spouses or dependent children asking whether the employee has changed from a self-and family to a self-only health benefits enrollment, individuals working on a contract, service, grant, cooperative agreement, or job for the Federal government, non-agency members of an agency's performance or other panel, and agency-appointed representatives of employees concerning information issued to the employee about fitness-for duty or agency-filed disability retirement procedures.

Optional Form 306 (EG)
September 1994
US Office of Personnel
Management

Form Approved
OMB No 3206-0182

Declaration for Federal Employment

GENERAL INFORMATION

1 FULL NAME

► Anthony S. Fauci, M.D.

2 SOCIAL SECURITY NUMBER

(b) (6)

3 PLACE OF BIRTH (Include City and State or Country)

► (b) (6)

4 DATE OF BIRTH (MM/DD/YY)

► (b) (6)

5 OTHER NAMES EVER USED (For example, maiden name, nickname, etc.)

►
►

6 PHONE NUMBERS (Include Area Codes)

(b) (6)

DAY ►

NIGHT ►

MILITARY SERVICE

7 Have you served in the United States Military Service? If your only active duty was training in the Reserves or National Guard, answer "NO"

If you answered "YES", list the branch, dates (MM/DD/YY), and type of discharge for all active duty military service

BRANCH

FROM

TO

TYPE OF DISCHARGE

(b) (6)

BACKGROUND INFORMATION

For all questions, provide all additional requested information under item 15 or on attached sheets. The circumstances of each event you list will be considered. However, in most cases you can still be considered for Federal jobs.

(b) (6)

ADDITIONAL QUESTIONS

(b) (6)



7H

CONTINUATION SPACE/AGENCY OPTIONAL QUESTIONS

- 15 Provide details requested in items 8 through 13 and 17c in the continuation space below or on attached sheets. Be sure to identify attached sheets with your name, Social Security Number, and item number, and to include ZIP Codes in all addresses. If any questions are printed below, please answer as instructed (these questions are specific to your position, and your agency is authorized to ask them)

(b) (6)

CERTIFICATIONS/ADDITIONAL QUESTION

APPLICANT: If you are applying for a position and have not yet been selected. Carefully review your answers on this form and any attached sheets. When this form and all attached materials are accurate, complete item 16/16a.

APPOINTEE: If you are being appointed. Carefully review your answers on this form and any attached sheets, including any other application materials that your agency has attached to this form. If any information requires correction to be accurate as of the date you are signing, make changes on this form or the attachments and/or provide updated information on additional sheets, initialing and dating all changes and additions. When this form and all attached materials are accurate, complete item 16/16b and answer item 17.

16 I certify that, to the best of my knowledge and belief, all of the information on and attached to this Declaration for Federal Employment, including any attached application materials, is true, correct, complete, and made in good faith. I understand that a false or fraudulent answer to any question on any part of this declaration or its attachments may be grounds for not hiring me, or for firing me after I begin work, and may be punishable by fine or imprisonment. I understand that any information I give may be investigated for purposes of determining eligibility for Federal employment as allowed by law or Presidential order. I consent to the release of information about my ability and fitness for Federal employment by employers, schools, law enforcement agencies, and other individuals and organizations, to investigators, personnel specialists, and other authorized employees of the Federal Government. I understand that for financial or lending institutions, medical institutions, hospitals, health care professionals, and some other sources of information, a separate specific release may be needed, and I may be contacted for such a release at a later date.

16a Applicant's Signature
(Sign in Ink)

Date 1-14-00

16b Appointee's Signature
(Sign in Ink)

1-14-00

APPOINTING OFFICER Enter Date of Appointment or Conversion
01-30-00

- 17 **Appointee Only (Respond only if you have been employed by the Federal Government before):** Your elections of life insurance during previous Federal employment may affect your eligibility for life insurance during your new appointment. These questions are asked to help your personnel office make a correct determination.

17a When did you leave your last Federal job?

17b When you worked for the Federal Government last time, did you waive Basic Life Insurance or any type of optional life insurance?

17c If you answered "Yes" to item 17b, did you later cancel the waiver(s)? If your answer to item 17c is "No," use item 15 to identify the type(s) of insurance for which waivers were not cancelled.

Date (MM/DD/YY)		
Yes	No	Don't Know

Optional Form 306 (Back)

September 1994

Optional Form 306
U.S. Office of Personnel
Management

Declaration for Federal Employment

Form Approved
OMB No. 3206-0182

INSTRUCTIONS

The information collected on this form is used to determine your acceptability for Federal employment and your enrollment status in the Government's Life Insurance program. You may be asked to complete this form at any time during the hiring process. Follow instructions that the agency provides. If you are selected, you will be asked to update your responses on this form and on other materials submitted during the application process and then to recertify that your answers are true before you are appointed.

Your Social Security Number is needed to keep our records accurate, because people may have the same name and birthdate. Executive Order 9397 also asks Federal agencies to use this number to help identify individuals in agency records. Giving us your SSN or other information is voluntary. However, if you do not give us your SSN or

any other information requested, we cannot process your application. Incomplete addresses and ZIP Codes may also slow processing.

You must answer all questions truthfully and completely. A false statement on any part of this declaration or attached forms or sheets may be grounds for not hiring you, or for firing you after you begin work. Also, you may be punished by fine or imprisonment (U.S. Code, title 18, section 1001).

Either type your responses to this form or print clearly in dark ink. If you need additional space, attach letter-size sheets (8 1/2" X 11"), including your name, Social Security Number, and item number on each sheet. It is recommended that you keep a photocopy of your completed form for your records.

NOTIFICATION OF PERSONNEL ACTION

1. Name (Last, First, Middle) FAUCI, ANTHONY S				2. Social Security Number (b) (6)		3. Date of Birth (b) (6)		4. Effective Date 08/07/2016															
FIRST ACTION				SECOND ACTION																			
(b) (6)				6-A. Code		6-B. Nature of Action																	
				6-C. Code		6-D. Legal Authority																	
				6-E. Code		6-F. Legal Authority																	
5-E. Code		5-F. Legal Authority		6-E. Code		6-F. Legal Authority																	
7. FROM: Position Title and Number DIRECTOR NIAID (b) (6)				15. TO: Position Title and Number DIRECTOR NIAID (b) (6)																			
8. Pay Plan		9. Occ. Code		10. Grade or Level		11. Step or Rate		12. Total Salary		13. Pay Basis		16. Pay Plan		17. Occ. Code		18. Grade or Level		19. Step or Rate		20. Total Salary/Award		21. Pay Basis	
										(b) (6)												(b) (6)	
14. Name and Location of Position's Organization National Institutes of Health National Institutes of Health Nat'l Inst Allergy & Infectious Diseases Ofc Dir BETHESDA MD USA												22. Name and Location of Position's Organization National Institutes of Health National Institutes of Health Nat'l Inst Allergy & Infectious Diseases Ofc Dir BETHESDA MD USA											
EMPLOYEE DATA																							
(b) (6)																							
POSITION DATA																							
(b) (6)																							
38. Duty Station Code (b) (6)												39. Duty Station (City - County - State or Overseas Location) BETHESDA Montgomery MD USA											
40. Agency Data				41.				42.				43.				44. PAR Number:							
45. Promotion (b) (6)																							
46. Employing Department or Agency Department of HHS - National Institutes of Health												50. Signature/Authentication and Title of Approving Official Electronically Signed by: (b) (6) Acting Director, Office of Human Resources											
47. Agency Code				48. Personnel Office ID (b) (6)				49. Approval Date 08/07/2016															

NOTIFICATION OF PERSONNEL ACTION

1. Name (Last, First, Middle) FAUCI, ANTHONY S				2. Social Security Number (b) (6)		3. Date of Birth (b) (6)		4. Effective Date 12/13/2016	
FIRST ACTION					SECOND ACTION				
5-A. Code					6-A. Code				
5-B. Nature of Action (b) (6)					6-B. Nature of Action				
5-C. Code					6-C. Code				
5-D. Legal Authority					6-D. Legal Authority				
5-E. Code					6-E. Code				
5-F. Legal Authority					6-F. Legal Authority				
7. FROM: Position Title and Number DIRECTOR NIAID (b) (6)					15. TO: Position Title and Number DIRECTOR NIAID (b) (6)				
8. Pay Plan					16. Pay Plan				
9. Occ. Code					17. Occ. Code				
10. Grade or Level					18. Grade or Level				
11. Step or Rate					19. Step or Rate				
12. Total Salary					20. Total Salary/Award				
13. Pay Basis (b) (6)					21. Pay Basis (b) (6)				
14. Name and Location of Position's Organization National Institutes of Health National Institutes of Health Nat'l Inst Allergy & Infectious Diseases Ofc Dir BETHESDA MD USA					22. Name and Location of Position's Organization National Institutes of Health National Institutes of Health Nat'l Inst Allergy & Infectious Diseases Ofc Dir BETHESDA MD USA				
EMPLOYEE DATA									
(b) (6)									
POSITION DATA									
(b) (6)									
38. Duty Station Code (b) (6)					39. Duty Station (City - County - State or Overseas Location) BETHESDA Montgomery MD USA				
40. Agency Data					44. PAR Number:				
45. Remarks (b) (6)									
46. Employing Department or Agency Department of HHS - National Institutes of Health					50. Signature/Authentication and Title of Approving Official Electronically Signed by: (b) (6) Acting Director, Office of Human Resources				
47. Agency Code					49. Approval Date 06/14/2017				
48. Personnel Office ID (b) (6)									

45

Executive Branch Personnel
Public Financial Disclosure Report(OGE Form 278e)

Filer's Information

FAUCI, Anthony S.

NIAD/OD -- Director, National Institute of Allergy and Infectious Diseases, DHHS/NIH

Date of Appointment: 2/1/1985

Other Federal Government Positions Held During the Preceding 12 Months:

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ **FAUCI, Anthony S** [electronically signed on 4/21/2020 by FAUCI, Anthony S in NEES]

Agency Ethics Official Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).
/s/ **TABAK, Lawrence Allan** [electronically signed on 5/18/2020 by TABAK, Lawrence Allan in NEES]

Other review conducted by

U.S office of Government Ethics Certification



1. Filer's Positions Held Outside United States Government

#	NAME	CITY, STATE	ORG TYPE	POSITION	FROM	TO
1	Doris Duke Charitable Foundation (DDCF) (Filer Changes)	New York, NY	Foundation	Member	10/1996	Present
2	McGraw-Hill Publishing Company (Filer Changes)	Burr Ridge, IL	Publisher/Journal	Editor, Associate	11/1983	Present

2. Filer's Employment Assets and Income

#	DESCRIPTION	EIF	VALUE	INCOME TYPE	INCOME AMOUNT
1	Jackson-Fillmore (Italian Restaurant), Partnership or Joint Venture, Restaurant), San Francisco, CA	N/A	\$1,001 - \$15,000		None
2	McGraw-Hill Publishers, Inc. - New York, New York, Book Royalty for editing "Harrison's Principles of Internal Medicine"	N/A	None	Rents and Royalties	\$100,001 - \$1,000,000
3	Attachment: 2019 - Filer - Revocable Trust - Account Summary				
4	Attachment: 2019 - Filer - Defined Benefit Plan - Account Summary				
5	Attachment: 2019 - Filer - Contributory IRA - Account Summary				
6	Attachment: 2019 - Spouse - Revocable Trust - Account Summary				

77

3. Filer's Employment Agreements and Arrangements

None

4. Filer's Sources of Compensation Exceeding \$5,000 in a year

None

5. Spouse's Employment Assets and Income

None

6. Other Assets and Income

#	DESCRIPTION	EIF	VALUE	INCOME TYPE	INCOME AMOUNT
1	Dreyfus Liquid Assets Class I - Money Market, Mutual Fund, Investment Fund, or Pool (Filer Changes)	Y	\$250,001 - \$500,000	Dividends	\$2,501 - \$5,000
2	Learning Quest 529 Education Plan for Child #3: Moderate track, Short-term Portfolio., Mutual Fund, Investment Fund, or Pool	Y	\$50,001 - \$100,000	Dividends	\$2,501 - \$5,000

7. Transactions

#	DESCRIPTION	TYPE	DATE	AMOUNT
1	Attachment: 2019 - Spouse - IRA Contributory - Transactions			
2	Attachment: 2019 - Spouse - Revocable Trust - Transactions			
3	Attachment: 2019 - Filer - Defined Benefit Plan - Transactions			
4	Attachment: 2019 - Filer - IRA Contributory - Transactions			
5	Attachment: 2019 - Filer - Revocable Trust - Transactions			

8. Liabilities

None

9. Gifts and Travel Reimbursements

#	SOURCE NAME	CITY, STATE	BRIEF DESCRIPTION	VALUE
1	Lurie Prize - Foundation for NIH (Filer Changes)	Bethesda,, MD	WAG - Attended the 2019 Awards Ceremony and served as presenter of the Lurie Prize in Biomedical Research on 03/13/2019 in Washington, DC	\$500

2	Reimbursement expense, Doris Duke Charitable Foundation (DDCF) (Filer Changes)	New York, NY	Reimbursement for travel to New York City on 11/11/2019 to attend meeting of the Board of Directors of the Doris Duke Charitable Foundation	\$422
3	Reimbursement expense, McGraw-Hill Publishing Company (Filer Changes)	Burr Ridge, IL	Travel expense reimbursement for trip to La Jolla, CA to attend meeting of the Editorial Board of Harrison's Principles of Internal Medicine (McGraw-Hill Publishing) from 07/07/2019 to 07/13/2019	\$6328
4	Research/America (Filer Changes)	Washington, DC	WAG - Attended Annual Advocacy Awards Dinner on March 13, 2019 in Washington, DC.	\$500

Endnotes

COVER PAGE COMMENTS

NEO Reviewer - DAVID L HARRIS: (05/01/2020 7:41 a.m.)

Initial Review 4/28/20 Dharrisadditional info requested from filer on 4/28/20 - additional info received from filer 4/30/20. Revisions made pursuant to filer. Compliant with applicable rules. DHarris



Schwab One® Trust Account of
ANTHONY S FAUCI TTEE
ANTHONY S FAUCI REVOCABLE TR
U/A DTD 03/19/2014

(b) (6)

Investment Detail - Cash and Money Market Funds [Sweep]

(b) (6)						
---------	--	--	--	--	--	--

Money Market Funds [Sweep]	Quantity	Market Price	Market Value	Current Yield	% of Account Assets
----------------------------	----------	--------------	--------------	---------------	---------------------

SCHWAB GOVT MONEY FUND: SWGXX	(b) (6)	(b) (6)	(b) (6)	(b) (6)	(b) (6)
-------------------------------	---------	---------	---------	---------	---------

Investment Detail - Mutual Funds

Bond Funds	Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis	Unrealized Gain or (Loss)
PIMCO INVESTMENT GRADE CREDIT BD INST SYMBOL: PIGIX	(b) (6)	(b) (6)	(b) (6)	(b) (6)	(b) (6)	(b) (6)	9,531.31
T ROWE PRICE SUMMIT MUNI INTERM INV SYMBOL: PRSMX	(b) (6)	(b) (6)	(b) (6)	(b) (6)	(b) (6)	(b) (6)	27,471.46

(b) (6)





Schwab One® Trust Account of
ANTHONY S FAUCI TTEE
ANTHONY S FAUCI REVOCABLE TR
U/A DTD 03/19/2014

Investment Detail - Mutual Funds (continued)

Equity Funds	Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis (b) (6)	Unrealized Gain or (Loss)
CIBC ATLAS DISCIPLINED EQTY FD INST SYMBOL: AWEIX							390,644.58
CIBC ATLAS INCM OPTTY FD INST SYMBOL: AWIIX							60,516.47
CIBC ATLAS MID CAP EQTY FD INST SYMBOL: AWMIX							69,199.24
HARDING LOEVNER INST EMRG MKTS CL I SYMBOL: HLMEX							43,767.74
JPMORGAN MID CAP VALUE L SYMBOL: FLMVX							31,301.93
MAINSTAY EPOCH GLOBAL EQTY YIELD I SYMBOL: EPSYX							7,723.88
MATTHEWS PACIFIC TIGER FD INSTL SYMBOL: MPTX							7,758.75
MFS INSTL INTL EQUITY SYMBOL: MIEIX							560.95



Schwab One® Trust Account of
ANTHONY S FAUCI TTEE
ANTHONY S FAUCI REVOCABLE TR
U/A DTD 03/19/2014

(b) (6)

Investment Detail - Mutual Funds (continued)

Equity Funds (continued)	Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis (b) (6)	Unrealized Gain or (Loss)
TWEEDY BROWNE GLOBAL VAL UE FUND SYMBOL: TBGVX							1,917.92
VANGUARD SMALL CAP INDEX ADMIRAL SHARE SYMBOL: VSMAX							8,325.13
VERSUS CAP MULTI MNGR REAL ESTATE INCM FD INST SYMBOL: VCMIX							2,373.59
VERSUS CAP REAL ASSET FUND SYMBOL: VCRRX							2,496.93



Brokerage Trust Account of
ANTHONY S FAUCI TTEE
FAUCI DEFINED BENEFIT PLAN
U/A DTD 12/08/1995

(b) (6)

Investment Detail - Mutual Funds (continued)

	Quantity	Market Price	Market Value	Account Assets	% of Assets	Average Cost Basis	Cost Basis (b) (6)	Unrealized Gain or (Loss)
Equity Funds (continued)								
CIBC ATLAS INCM OPPTY								
FD INST								
SYMBOL: AWMIX								32,675.13
CIBC ATLAS MID CAP EQTY								
FD INST								11,835.18
SYMBOL: AWMIX								
EDGEWOOD GROWTH INSTL								
SYMBOL: EGFIX								13,843.88
HAMLIN HIGH DIV EQTY								
INSTL								20,982.51
SYMBOL: HHDFX								
IWA INTL FD CL I								
SYMBOL: IMQX								(511.41)
JPMORGAN MID CAP VALUE								
L								33,127.49
SYMBOL: FLMVX								
MAINSTAY EPOCH GLOBAL								
EQTY YIELD I								7,352.56
SYMBOL: EPSYX								
MATTHEWS PACIFIC TIGER								
FD INSTL								4,709.05
SYMBOL: MIPTX								
TWEEDY BROWNE GLOBAL								
VAL								804.96
UE FUND								
SYMBOL: TBGVX								

Schwab has provided accurate gain and loss information wherever possible for most investments. Cost basis data may be incomplete or unavailable for some of your holdings. Please see "Endnotes for Your Account" section for an explanation of the endnote codes and symbols on this statement.



**Brokerage Trust Account of
ANTHONY S FAUCITTEE
FAUCI DEFINED BENEFIT PLAN
U/A DTD 12/08/1995**

Investment Detail - Mutual Funds (continued)

Equity Funds (continued)	Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis (b) (6)	Unrealized Gain or (Loss)
VIRTUS VONTOBEL EMRG \diamond							
MKTS OPTTY FD I							
SYMBOL: HIEMX							8,568.30

(b) (6)

(b) (6)

Schwab has provided accurate gain and loss information wherever possible for most investments. Cost basis data may be incomplete or unavailable for some of your holdings. Please see "Endnotes for Your Account" section for an explanation of the endnote codes and symbols on this statement.





Contributory IRA of
ANTHONY S FAUCI
CHARLES SCHWAB & CO INC CUST
IRA CONTRIBUTORY

(b) (6)

Investment Detail - Bank Sweep

						% of Account
						(b) (6)

Investment Detail - Mutual Funds

Equity Funds	Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis	Unrealized Gain or (Loss)
CIBC ATLAS DISCIPLINED EQTY FD INST SYMBOL: AWEIX						(b) (6)	77,106.95
CIBC ATLAS INCM OPTTY FD INST SYMBOL: AWIIX							10,355.63
CIBC ATLAS MID CAP EQTY FD INST SYMBOL: AWMIX							12,563.65
EDGEWOOD GROWTH INSTL SYMBOL: EGFIX							2,814.56
JPMORGAN MID CAP VALUE L SYMBOL: FLMVX							13,021.74

Schwab has provided accurate gain and loss information wherever possible for most investments. Cost basis data may be incomplete or unavailable for some of your holdings. Please see "Endnotes for Your Account" section for an explanation of the endnote codes and symbols on this statement.



Contributory IRA of
ANTHONY S FAUCI
CHARLES SCHWAB & CO INC CUST
IRA CONTRIBUTORY

Investment Detail - Mutual Funds (continued)

Equity Funds (continued)	Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis	Unrealized Gain or (Loss)
MAINSTAY EPOCH GLOBAL ⁰ EQTY YIELD I SYMBOL: EPSYX						(b) (6)	2,634.55
MATTHEWS PACIFIC TIGER FD INSTL SYMBOL: MIPTX							1,633.63
MFS INSTL INTL EQUITY SYMBOL: MIEIX							1,476.21
TWEEDY BROWNE GLOBAL VAL UE FUND SYMBOL: TBGVX							2,416.73
VIRTUS VONTOBEL EMRG MKTS OPPTY FD I SYMBOL: HIEMX							2,068.19

(b) (6)

(b) (6)

Schwab has provided accurate gain and loss information whenever possible for most investments. Cost basis data may be incomplete or unavailable for some of your holdings. Please see "Endnotes for Your Account" section for an explanation of the endnote codes and symbols on this statement.

(b) (6)

(b) (6)

Investment Detail - Cash and Money Market Funds [Sweep]

(b) (6)

Money Market Funds [Sweep]
SCHWAB GOVT MONEY FUND: SWGXX

Quantity	Market Price	Market Value	Current Yield	% of Account Assets
				(b) (6)
				(b) (6)

Investment Detail - Mutual Funds

Bond Funds
T ROWE PRICE SUMMIT MUNI
INTERM INV
SYMBOL: PRSMX

Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis	Unrealized Gain or (Loss)
					(b) (6)	7,285.09

Total Bond Funds

7,285.09

Equity Funds
CIBC ATLAS INCM OPPTY
FD INST
SYMBOL: AWIIX

Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis	Unrealized Gain or (Loss)
					(b) (6)	23,330.02



(b) (6)

Investment Detail - Mutual Funds (continued)

(b) (6)

Equity Funds (continued)	Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis (b) (6)	Unrealized Gain or (Loss)
JPMORGAN MID CAP VALUE							35,913.49
SYMBOL: FLNVX							
MAINSTAY EPOCH GLOBAL							165.43
EQTY YIELD I							
SYMBOL: EPSYX							
PARNASSUS CORE EQTY FD							114,528.61
INST							
SYMBOL: PRILX							
PAX SMALL CAP INST							6,263.14
SYMBOL: PXSIX							
TOUCHSTONE GLOBAL ESG							55,016.83
EQUITY INST							
SYMBOL: TROCX							

(b) (6)



Contributor IRA of
(b) (6)
CHARLES SCHWAB & CO INC CUST
IRA CONTRIBUTORY

Investment Detail - Bank Sweep

(b) (6)

Investment Detail - Mutual Funds

Equity Funds	Quantity	Market Price	Market Value	% of Account Assets	Average Cost Basis	Cost Basis	Unrealized Gain or (Loss)
BOSTON COMMON ESG IMPACT INTL FD SYMBOL: BCAIX						(b) (6)	2,989.13
CIBC ATLAS INCM OPPTY FD INST SYMBOL: AWIIX							2,599.90
PARNASSUS CORE EQTY FD INST SYMBOL: PRILX							294.49
TOUCHSTONE GLOBAL ESG EQUITY INST SYMBOL: TROCX							(2,608.97)
						(b) (6)	


Schwab has provided accurate gain and loss information wherever possible for most investments. Cost basis data may be incomplete or unavailable for some of your holdings. Please see "Endnotes for Your Account" section for an explanation of the endnote codes and symbols on this statement.



Accounts (https://client.schwab.com/secure/cc/accounts)

- Products (https://client.schwab.com/secure/cc/products)
- Specialty (https://client.schwab.com/secure/cc/guidance)
- Service (https://client.schwab.com/secure/)
- Summary (https://client.schwab.com/secure/cc/accounts/summary)
- Balances (https://client.schwab.com/secure/cc/accounts/balances)
- History (https://client.schwab.com/secure/cc/accounts/historynew)
- Statements (https://client.schwab.com/secure/cc/accounts/statementshistory)
- Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payment)

Page last updated: 05:34 PM ET, 04/20/2020 Refresh Export Print



Transactions From 01/01/2019 To 12/31/2019

Date Action Details Symbol Description Quantity Price Fees & Comm Amount

12/30/2019	Cash Dividend	AMIX	CIBC ATLAS INCM OPTY FD INST			\$89.66	
12/27/2019	Cash Dividend	TROCX	TOUCHSTONE GLOBAL ESG EQUITY INST			\$527.72	
12/27/2019	Cash Dividend	PRILX	PARNASUS CORE EQTY FD INST			\$29.15	
12/17/2019	Cash Dividend	BCAIX	BOSTON COMMON ESG IMPACT INTL FD			\$450.46	
12/16/2019 as of	Bank Interest						
12/11/2019	Reinvest Shares	TROCX	TOUCHSTONE GLOBAL ESG EQUITY INST				
12/11/2019	Long Term Cap Gain Reinvest	TROCX	TOUCHSTONE GLOBAL ESG EQUITY INST				
11/21/2019	Long Term Cap Gain Reinvest	PRILX	PARNASUS CORE EQTY FD INST				
11/21/2019	Reinvest Shares	PRILX	PARNASUS CORE EQTY FD INST				
11/18/2019 as of	Bank Interest						
11/15/2019	Bank Interest						
10/16/2019 as of	Bank Interest						
10/15/2019	Bank Interest						
09/30/2019	Cash Dividend	PRILX	PARNASUS CORE EQTY FD INST			\$26.84	
09/27/2019	Cash Dividend	AMIX	CIBC ATLAS INCM OPTY FD INST			\$60.81	
09/15/2019	Bank Interest						

26

4/20/2020

Charles Schwab Client Center



(b) (6)

06/28/2019	Cash Dividend	PRILX	PARNASSUS CORE EQTY FD	INST	\$21.24
06/27/2019	Cash Dividend	AWIX	CIBC ATLAS INCM OPTY FD	INST	\$90.18

06/17/2019 as of Bank Interest (b) (6)

05/16/2019 as of Bank Interest (b) (6)

05/15/2019 Bank Interest (b) (6)

04/16/2019 as of Bank Interest (b) (6)

03/29/2019 Cash Dividend PRILX PARNASSUS CORE EQTY FD INST \$25.99

03/28/2019 Cash Dividend AWIX CIBC ATLAS INCM OPTY FD INST \$67.27

03/15/2019 as of Bank Interest (b) (6)

02/19/2019 as of Bank Interest (b) (6)

01/16/2019 as of Bank Interest (b) (6)

Transactions Total

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institutions referenced on the Balances detail page. Your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

Accounts (https://client.schwab.com/secure/cc/accounts) Trade (https://client.schwab.com/secure/cc/trade) Research (https://client.schwab.com/secure/cc/research) Specialty (https://client.schwab.com/secure/cc/products) Summary (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/balances) Positions (https://client.schwab.com/secure/cc/positions) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payments_overview) Statements (https://client.schwab.com/secure/cc/accounts/statements) SIPC (https://client.schwab.com/secure/cc/sipc) (b) (6)

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

Charles Schwab & Co., Inc. and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC) (https://www.sipc.org) ("Schwab"), a duly registered investment advisor and broker dealer. Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"), Schwab and CSIA are subsidiaries of The Charles Schwab Corporation. Deposit and lending products and services are offered by Charles Schwab Bank, SSB, Member FDIC and an Equal Housing Lender ("Schwab Bank").

Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured, in aggregate, up to \$250,000 per Affiliated Bank, per depositor, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unswept or intra-day cash, net credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC) (https://www.sipc.org) are not deposits or obligations of the Affiliated Banks, are subject to investment risk, are not FDIC insured, and are not Affiliated Bank-guaranteed. Charles Schwab & Co., Inc. and the Affiliated Banks are separate entities and are all affiliates of The Charles Schwab Corporation.

© 2020 Charles Schwab & Co., Inc. All rights reserved. Member SIPC (https://www.sipc.org). Unauthorized access is prohibited. Usage will be monitored. Privacy (https://client.schwab.com/secure/cc/privacy) USA Patriot Act (https://client.schwab.com/secure/cc/patriot_act.html) SIPC (https://client.schwab.com/secure/cc/sipc.html) Compliance (https://client.schwab.com/secure/cc/compliance) (b) (6)

Agreements (https://client.schwab.com/secure/cc/legal/compliance/agreements) Privacy (https://client.schwab.com/secure/cc/privacy) USA Patriot Act (https://client.schwab.com/secure/cc/patriot_act.html) SIPC (https://client.schwab.com/secure/cc/sipc.html) Compliance (https://client.schwab.com/secure/cc/compliance) (b) (6)




Accounts (https://client.schwab.com/secure/cc/accounts) Trade (https://client.schwab.com/secure/cc/trade) Research (https://client.schwab.com/secure/

Products (https://client.schwab.com/secure/cc/products) Specialty (https://client.schwab.com/secure/cc/guidance) Service (https://client.schwab.com/secure/

Summary (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/accounts/balances) History (https://client.schwab.com/secure/cc/accounts/historynew) Statements (https://client.schwab.com/secure/cc/accounts/statements/history) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payment

Page last updated: 05:24 PM ET, 04/20/2020 Refresh Export Print



Transactions From 01/01/2019 To 12/31/2019

Date Action Details Symbol Description Quantity Price Fees & Comm Amount

12/31/2019 Cash Dividend PRSMX T ROWE PRICE SUMMIT MUNI INTERM INV \$752.78

12/31/2019 Cash Dividend SWGXX SCHWAB GOVT MONEY FUND

12/31/2019 Buy Trade Details SWGXX SCHWAB GOVT MONEY FUND

12/30/2019 Cash Dividend AWMX CIBC ATLAS INCM OPTV FD INST \$397.74

12/30/2019 Buy Trade Details SWGXX SCHWAB GOVT MONEY FUND

12/27/2019 Cash Dividend TROCX TOUCHSTONE GLOBAL ESG EQUITY INST \$3,081.96

12/27/2019 Cash Dividend PRILX PARANASSUS CORE EQTY FD INST \$1,622.64

12/20/2019 Buy Trade Details SWGXX SCHWAB GOVT MONEY FUND

12/19/2019 Cash Dividend FLMVX JPMORGAN MID CAP VALUE L \$2,317.76

12/12/2019 Long Term Cap FLMVX JPMORGAN MID CAP VALUE L \$8,685.94

12/12/2019 Reinvest Shares FLMVX JPMORGAN MID CAP VALUE L

12/11/2019 Reinvest Shares TROCX TOUCHSTONE GLOBAL ESG EQUITY INST

12/11/2019 Long Term Cap TROCX TOUCHSTONE GLOBAL ESG EQUITY INST \$5,172.73

12/11/2019 Buy Trade Details SWGXX SCHWAB GOVT MONEY FUND \$11.83

(b) (6)

Reversible Invest
Transactions 2019

(b) (6)

DJIA (https://client.schwab.com/secure/cc/n/gw/wsood?path=/retail/research/markets/chart&symbol=\$DJIA) 23,650.44 -592.05 (-2.44%)

https://client.schwab.com/Apps/accounts/transactionhistory/#/

(b) (6)

NASDAQ (https://client.schwab.com/secure/cc/n/gw/wsd/path=/retail/research/markets/chart/symbol=\$SPX;fund=FUND) SCHWAB GOVT MONEY INST
8,580.73 -39.41 (-1.03%)
RUSSELL 2000 (https://client.schwab.com/secure/cc/n/gw/wsd/path=/retail/research/markets/chart/symbol=\$RUS2000) SCHWAB GOVT MONEY INST
1,213.35 -15.75 (-1.28%)
SP500 (https://client.schwab.com/secure/cc/n/gw/wsd/path=/retail/research/markets/chart/symbol=\$SPX;fund=FUND) SCHWAB GOVT MONEY INST
2,823.16 -51.40 (-1.79%)
NASDAQ (https://client.schwab.com/secure/cc/n/gw/wsd/path=/retail/research/markets/chart/symbol=\$SPX;fund=FUND) SCHWAB GOVT MONEY INST
8,580.73 -39.41 (-1.03%)

Buy

06/20/2019	Cash Dividend	PRIX	PARMASSUS CORE EQTY FD	INST	\$1,182.47
06/28/2019	Cash Dividend	EPYX	MAINSTAY EPOCH GLOBAL	INST	\$33.49
06/28/2019	Buy	SWCXX	SCHWAB GOVT MONEY FUND		-5892.24
06/27/2019	Cash Dividend	AWIX	CIBC ATLAS INCM OPTFY FD	INST	\$892.24
06/21/2019	Buy	SWGXX	SCHWAB GOVT MONEY FUND		-5870.89
06/20/2019	Cash Dividend	PXSIX	PAX SMALL CAP	INST	\$870.89

Transactions Total

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institutions referenced on the Balances detail page; your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

Accounts (https://client.schwab.com/secure/cc/accounts) Trade (https://client.schwab.com/secure/cc/trade) Research (https://client.schwab.com/secure/cc/research) Products (https://client.schwab.com/secure/cc/products) Specialty (https://client.schwab.com/secure/cc/specialty) Service (https://client.schwab.com/secure/cc/service) Summary (https://client.schwab.com/secure/cc/summary) Balances (https://client.schwab.com/secure/cc/balances) Positions (https://client.schwab.com/secure/cc/positions) History (https://client.schwab.com/secure/cc/history/new) Statements (https://client.schwab.com/secure/cc/statements) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payments_overview)

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

Charles Schwab & Co., Inc. and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) ("Schwab"), a dually registered investment advisor and broker dealer. Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"), Schwab and CSIA are subsidiaries of The Charles Schwab Corporation. Deposit and lending products and services are offered by Charles Schwab Bank, SSB, Member FDIC and an Equal Housing Lender ("Schwab Bank").

Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured in aggregate, up to \$250,000 per depositor, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unsegregated cash, not credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) are not deposits or obligations of the Affiliated Banks, are subject to investment risk, are not FDIC insured, may lose value, and are not Affiliated Bank-guaranteed. Charles Schwab & Co., Inc. and the Affiliated Banks are separate entities and are all affiliates of The Charles Schwab Corporation.

© 2020 Charles Schwab & Co., Inc. All rights reserved. Member SIPC (https://www.sipc.org). Unauthorized access is prohibited. Usage will be monitored.

Agreements (https://client.schwab.com/secure/cc/legal_compliance/agreements) Privacy (https://client.schwab.com/secure/cc/privacy) USA Patriot Act (https://client.schwab.com/secure/cc/legal_compliance/usa_patriot_act.html) SIPC® (https://www.sipc.org) Site Map (https://client.schwab.com/secure/cc/legal_compliance/site_map) Site Help (https://client.schwab.com/secure/cc/help) Support Session Bank Client Complaint (https://client.schwab.com/secure/cc/legal_compliance/consumer-complaint-notice.html)

Quote

Show Indices
Symbol Lookup



Accounts (https://client.schwab.com/secure/cc/accounts)

Trade (https://client.schwab.com/secure/cc/trade)

Research (https://client.schwab.com/secure/

Products (https://client.schwab.com/secure/cc/products) Specialty (https://client.schwab.com/secure/cc/guidance) Service (https://client.schwab.com/secure/

Summary (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/accounts/balances) History (https://client.schwab.com/secure/cc/accounts/historynew) Statements (https://client.schwab.com/secure/cc/accounts/statements/history) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payment

Independent Investment Advisor
CIBC PRIVATE WEALTH ADVIS, INC.
CIBC PRIVATE WEALTH MANAGEMENT
Contact your advisor
Not affiliated with Schwab

Transactions From 01/01/2019 To 12/31/2019

Date ▼ Action Details Symbol Description Quantity Price Fees & Comm Amount

(b) (6)

(b) (6)

(b) (6)

(b) (6)

(b) (6)

(b) (6)

(b) (6)

(b) (6)

(b) (6)

(b) (6)

46

4/20/2020

Charles Schwab Client Center

(b) (6)

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%
8,560.73	-89.41 (-1.03%)	Cash Dividend	03/28/2019	2,823.16	-51.40 (-1.79%)	Russell 2000 Index	1,213,342.15	-1.28%

Transactions Total

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institution(s) referenced on the Balances detail page, your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

Accounts (https://client.schwab.com/secure/cc/accounts) Trade (https://client.schwab.com/secure/cc/trade) Research (https://client.schwab.com/secure/cc/research) Services (https://client.schwab.com/secure/cc/services) Positions (https://client.schwab.com/secure/cc/positions) History (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/balances) Statements (https://client.schwab.com/secure/cc/statements/summary) Transfers & Payments (https://client.schwab.com/secure/cc/transfers_and_payments/overview)

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

Charles Schwab & Co., Inc. and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab SIPC (https://www.sipc.org) ("Schwab"), a dualy registered investment advisor and broker dealer, Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"), Schwab and CSIA are subsidiaries of Housing Lender Bank ("Schwab Bank"). Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured, in aggregate, up to \$250,000 per FDIC-insured bank, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unswept or intra-day cash, net credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) are not deposits or obligations of the Affiliated Banks, and subject to separate entities and are all affiliates of The Charles Schwab Corporation. © 2020 Charles Schwab & Co., Inc. All rights reserved. Member SIPC (https://www.sipc.org). Unauthorized access is prohibited. Usage will be monitored.

Agreements (https://client.schwab.com/secure/cc/legal/compliance/agreements) Privacy (https://client.schwab.com/secure/cc/privacy) SIPC (https://www.sipc.org) USA Patriot Act (https://client.schwab.com/secure/cc/patriot_act.html) FDIC Insurance (https://client.schwab.com/secure/cc/legal/compliance/fdic_insurance.html) Site Map (https://client.schwab.com/secure/cc/site_map) Support Section Bank Client Complaint (https://client.schwab.com/secure/cc/complaint-notice.html)





86

Accounts (https://client.schwab.com/secure/cc/accounts)

Trade (https://client.schwab.com/secure/cc/trade)

Research (https://client.schwab.com/secure/

Products (https://client.schwab.com/secure/cc/products)


Specialty (https://client.schwab.com/secure/cc/guidance)

Service (https://client.schwab.com/secure/

Summary (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/accounts/balances)

Positions (https://client.schwab.com/secure/cc/accounts/positions) History (https://client.schwab.com/secure/cc/accounts/historynew)

Statements (https://client.schwab.com/secure/cc/accounts/statements/history) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payment)



Transactions From 01/01/2019 To 12/31/2019

Date Action Details Symbol Description Quantity Price Fees & Comm Amount

12/31/2019	Cash Dividend	PIGIX	FINVCO INVESTMENT GRADE CREDIT BD INST			\$1,557.18
12/30/2019	Cash Dividend	AWIIX	CIBC ATLAS INCM OPTV FD INST			\$1,616.95
12/30/2019	Cash Dividend	H4DFX	HAALIN HIGH DIV Eqty INSTL			\$1,614.99
12/30/2019	Reinvest Dividend	AWIIX	CIBC ATLAS DISCIPLINED Eqty FD INST			\$5,234.46
12/30/2019	Reinvest Shares	AWIIX	CIBC ATLAS DISCIPLINED Eqty FD INST			\$5,234.46
12/30/2019	Reinvest Shares	AWIIX	CIBC ATLAS DISCIPLINED Eqty FD INST			-\$5,234.46
12/20/2019	Reinvest Shares	HIEMX	VIRTUS VONTOBEL EMRG MKTS OPTV FD I			-\$353.75
12/20/2019	Reinvest Shares	HIEMX	VIRTUS VONTOBEL EMRG MKTS OPTV FD I			-\$2,903.43
12/20/2019	Reinvest Shares	HIEMX	VIRTUS VONTOBEL EMRG MKTS OPTV FD I			-\$247.29
12/20/2019	Long Term Cap	HIEMX	VIRTUS VONTOBEL EMRG MKTS OPTV FD I			\$353.75
12/20/2019	Reinvest Dividend	HIEMX	VIRTUS VONTOBEL EMRG MKTS OPTV FD I			\$2,903.43
12/20/2019	Short Term Cap	HIEMX	VIRTUS VONTOBEL EMRG MKTS OPTV FD I			\$247.29
12/19/2019	Long Term Cap	AWIIX	CIBC ATLAS DISCIPLINED Eqty FD INST			\$8,037.19
12/19/2019	Gain Reinvest	AWIIX	CIBC ATLAS DISCIPLINED Eqty FD INST			\$8,037.19
12/19/2019	Reinvest Dividend	FLMXX	JPMORGAN MID CAP VALUE L			\$2,574.68
12/19/2019	Long Term Cap	EGFIX	EDGEWOOD GROWTH INSTL			\$402.67

(b) (6)

Original Benefit Plan Information 2019

(b) (6)

4/20/2020

Charles Schwab Client Center

(b) (6)

/mbol=\$IXIC)

12/19/2019	Reinvest Shares	NASDAQ (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\$SPX	EGFIX	EDGEWOOD GROWTH INSTL	-\$2,574.68
12/18/2019	Long Term Cap Gain Reinvest	2,823.16 -51.40 (-1.79%)	IVQX	IVA INTL FD CL I	\$789.81
12/18/2019	Reinvest Dividend	Russell 2000 (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\$RUS2000	IVQX	IVA INTL FD CL I	\$1,031.57
12/18/2019	Short Term Cap Gain Reinvest	1,213.35 -15.75 (-1.28%)	IVQX	IVA INTL FD CL I	\$179.38
12/18/2019	Reinvest Shares		IVQX	IVA INTL FD CL I	-\$789.81
12/18/2019	Reinvest Shares		IVQX	IVA INTL FD CL I	-\$1,031.57
12/18/2019	Reinvest Shares		IVQX	IVA INTL FD CL I	-\$179.38
12/17/2019	Cash Dividend		MIPTX	MATTHEWS PACIFIC TIGER FD INSTL	\$1,072.89
12/17/2019	Long Term Cap Gain Reinvest		MIPTX	MATTHEWS PACIFIC TIGER FD INSTL	\$4,632.85
12/17/2019	Reinvest Shares		MIPTX	MATTHEWS PACIFIC TIGER FD INSTL	-\$4,632.85
12/16/2019 as of 12/15/2019	Bank Interest				(b) (6)
12/12/2019	Cash Dividend		TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND	\$776.18
12/12/2019	Long Term Cap Gain Reinvest		FLMVX	JPMORGAN MID CAP VALUE L	\$7,427.04
12/12/2019	Short Term Cap Gain Reinvest		TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND	\$43.51
12/12/2019	Long Term Cap Gain Reinvest		TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND	\$93.98
12/12/2019	Reinvest Shares		FLMVX	JPMORGAN MID CAP VALUE L	-\$7,427.04
12/12/2019	Reinvest Shares		TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND	-\$93.98
12/12/2019	Reinvest Shares		TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND	-\$43.51
12/10/2019	Long Term Cap Gain Reinvest		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I	\$1,229.94
12/10/2019	Reinvest Dividend		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I	\$307.83
12/10/2019	Reinvest Shares		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I	-\$1,229.94
12/10/2019	Reinvest Shares		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I	-\$307.83
11/29/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST	\$1,634.66
11/18/2019 as of 11/15/2019	Bank Interest				(b) (6)
11/12/2019	Advisor Fee				
11/07/2019	Journal				



Quote

Show Indices
Symbol Lookup
 DJIA (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\$DJI)
 23,650.44 -592.05 (-2.44%)

https://client.schwab.com/Apps/accounts/transactionhistory/#/

11/06/2019	Sell	NASDAQ (https://client.schwab.com/secure/cc/nn/gw/wscd?path=/retail/research/markets/chart&symbol=\$SPX)	8,560.75 -55.41 (-1.03%)	EQTY FD INST	\$99,985.00
		S&P 500 (https://client.schwab.com/secure/cc/nn/gw/wscd?path=/retail/research/markets/chart&symbol=\$SPX)	2,623.16 -51.40 (-1.79%)		
		Russ 1000 (https://client.schwab.com/secure/cc/nn/gw/wscd?path=/retail/research/markets/chart&symbol=\$RUS1000)	1,213.35 -15.75 (-1.28%)	PIMCO INVESTMENT GRADE CREDIT BD INST	\$99,985.00
10/31/2019	Cash Dividend	PIGIX		PIMCO INVESTMENT GRADE CREDIT BD INST	\$1,834.93
10/16/2019 as of 10/15/2019	Bank Interest				(b) (6)
09/30/2019	Cash Dividend	PIGIX		PIMCO INVESTMENT GRADE CREDIT BD INST	\$1,696.65
09/30/2019	Reinvest Dividend	EPSYX		MAINSTAY EPOCH GLOBAL EQTY YIELD I	\$398.56
09/30/2019	Reinvest Shares	EPSYX		MAINSTAY EPOCH GLOBAL EQTY YIELD I	-\$398.56
09/27/2019	Cash Dividend	AWIIX		CIBC ATLAS INCM OPPTY FD INST	\$1,096.76

Transactions Total

(b) (6)

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institution(s) referenced on the Balances detail page, your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

Accounts (https://client.schwab.com/secure/cc/accounts) Trade (https://client.schwab.com/secure/cc/trade) Research (https://client.schwab.com/secure/cc/research) Products (https://client.schwab.com/secure/cc/products) Specialty (https://client.schwab.com/secure/cc/guidance) Service (https://client.schwab.com/secure/cc/service) Summary (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/accounts/balances) Positions (https://client.schwab.com/secure/cc/accounts/positions) History (https://client.schwab.com/secure/cc/accounts/historynew) Statements (https://client.schwab.com/secure/cc/accounts/statements/history) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payments_overview)

↑ Back to Top

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

(b) (6)

Charles Schwab & Co., Inc., and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) ("Schwab"). Schwab Intelligent Portfolios® and Schwab Intelligent Portfolios Premium™ are made available through Charles Schwab & Co., Inc. ("Schwab"), a dually registered investment advisor and broker dealer. Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"). Schwab and CSIA are subsidiaries of The Charles Schwab Corporation. Deposit and lending products and services are offered by Charles Schwab Bank, SSB Member FDIC and an Equal Housing Lender ("Schwab Bank").

Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured, in aggregate, up to \$250,000 per Affiliated Bank, per depositor, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unswept or intra-day cash, net credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) are not deposits or obligations of the Affiliated Banks, are subject to investment risk, are not FDIC insured, may lose value, and are not Affiliated Bank-guaranteed. Charles Schwab & Co., Inc. and the Affiliated Banks are separate entities and are all affiliates of The Charles Schwab Corporation.

© 2020 Charles Schwab & Co., Inc. All rights reserved. Member SIPC (https://www.sipc.org). Unauthorized access is prohibited. Usage will be monitored.

Agreements (https://client.schwab.com/secure/cc/nn/legal_compliance/agreements) Privacy (https://client.schwab.com/secure/cc/nn/security/privacy) SchwabSafe (https://client.schwab.com/secure/cc/nn/security/schwabsafe) USA Patriot Act (https://client.schwab.com/secure/cc/nn/legal_compliance/usa_patriot_act.html) SIPC® (https://client.schwab.com/secure/cc/nn/legal_compliance/sipc.html) FDIC Insurance (https://client.schwab.com/secure/cc/nn/legal_compliance/fdic_insurance.html) Site Map (https://client.schwab.com/secure/cc/nn/sitemap) Site Help (https://client.schwab.com/secure/cc/help/schwab_com/page_features/help) Support Session Bank Client Complaint (https://client.schwab.com/secure/cc/nn/legal_compliance/consumer-complaint-notice.html)

<https://client.schwab.com/secure/cc/accounts>[Messages](#)[Contact Us](#)[Help](#)[Accounts \(https://client.schwab.com/secure/cc/accounts\)](https://client.schwab.com/secure/cc/accounts)[Trade \(https://client.schwab.com/secure/cc/trade\)](https://client.schwab.com/secure/cc/trade)[Research \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Products \(https://client.schwab.com/secure/cc/products\)](https://client.schwab.com/secure/cc/products)[Specialty \(https://client.schwab.com/secure/cc/guidance\)](https://client.schwab.com/secure/cc/guidance)[Service \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Summary \(https://client.schwab.com/secure/cc/accounts/summary\)](https://client.schwab.com/secure/cc/accounts/summary)[Balances \(https://client.schwab.com/secure/cc/accounts/balances\)](https://client.schwab.com/secure/cc/accounts/balances)[Positions \(https://client.schwab.com/secure/cc/accounts/positions\)](https://client.schwab.com/secure/cc/accounts/positions)[History \(https://client.schwab.com/secure/cc/accounts/historynew\)](https://client.schwab.com/secure/cc/accounts/historynew)[Statements \(https://client.schwab.com/secure/cc/accounts/statements/history\)](https://client.schwab.com/secure/cc/accounts/statements/history)[Transfers & Payments \(https://client.schwab.com/secure/cc/accounts/transfers_and_payment\)](https://client.schwab.com/secure/cc/accounts/transfers_and_payment)Page last updated: 05:15 PM ET, 04/20/2020 [Refresh](#) [Export](#) [Print](#)

Transactions From 01/01/2019 To 12/31/2019

Date ▼	Action	Details	Symbol	Description*	Quantity	Price	Fees & Comm	Amount
09/19/2019	Bank Interest							(b) (6)
09/16/2019 as of 09/15/2019	Bank Interest							(b) (6)
08/30/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST				\$1,956.73
08/18/2019 as of 08/15/2019	Bank Interest							(b) (6)
08/12/2019	Advisor Fee							(b) (6)
07/31/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST				\$1,837.94
07/16/2019 as of 07/15/2019	Bank Interest							(b) (6)
06/28/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST				\$1,759.69
06/28/2019	Cash Dividend		HHDFX	HAMLIN HIGH DIV EQTY INSTL				\$2,040.13
06/28/2019	Reinvest Dividend		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I				\$854.72
06/28/2019	Reinvest Shares		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I		(b) (6)		-\$854.72
06/27/2019	Cash Dividend		AWIIX	CIBC ATLAS INCM OPPTY FD INST				\$1,445.98
06/17/2019 as of 06/15/2019	Bank Interest							(b) (6)
05/31/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST				\$1,998.92


[Show Indicators](#)
[Symbol Lookup](#)
[DJIA \(https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\\$DJIA\)](https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=$DJIA)
 23,650.44 -592.05 (-2.44%)

(b) (6)

04/30/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST	\$1,852.18
04/24/2019	Sell	Trade Details	HHDFX	HAMLIN HIGH DIV EQTY INSTL	\$199,985.00
04/24/2019	Sell	Trade Details	IYQX	IYA INTL FD CL I	\$44,985.00
04/24/2019	Buy	Trade Details	AWIX	CIBC ATLAS INCM OPPTY FD INST	-\$100,015.00
04/24/2019	Sell	Trade Details	TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND	\$34,985.00
04/24/2019	Buy	Trade Details	EGFIX	EDGEWOOD GROWTH INSTL	-\$50,015.00
04/24/2019	Buy	Trade Details	HIEMX	VIRTUS VONTOBEL EMRG MKTS OPPTY FD I	-\$100,015.00
04/24/2019	Buy	Trade Details	MIPTX	MATTHEWS PACIFIC TIGER FD INSTL	-\$100,015.00
04/16/2019 as of 04/15/2019	Bank Interest				
04/15/2019	Journal				
03/29/2019	Reinvest Dividend		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I	\$672.56
03/29/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST	\$1,894.44
03/29/2019	Reinvest Shares		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I	-\$672.56
03/28/2019	Cash Dividend		AWIX	CIBC ATLAS INCM OPPTY FD INST	\$656.87
03/18/2019 as of 03/15/2019	Bank Interest				
02/28/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST	\$1,771.06
02/19/2019 as of 02/15/2019	Bank Interest				
02/11/2019	Advisor Fee				
01/31/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST	\$1,723.60
01/16/2019 as of 01/15/2019	Bank Interest				
Transactions Total					

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institution(s) referenced on the Balances detail page, your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

Accounts (<https://client.schwab.com/secure/cc/accounts>) Trade (<https://client.schwab.com/secure/cc/trade>) Research (<https://client.schwab.com/secure/cc/research>) Products (<https://client.schwab.com/secure/cc/products>) Specialty (<https://client.schwab.com/secure/cc/guidance>) Service (<https://client.schwab.com/secure/cc/service>) Summary (<https://client.schwab.com/secure/cc/accounts/summary>) Balances (<https://client.schwab.com/secure/cc/accounts/balances>) Positions (<https://client.schwab.com/secure/cc/accounts/positions>) History (<https://client.schwab.com/secure/cc/accounts/historynew>) Statements (<https://client.schwab.com/secure/cc/accounts/statements/history>) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payments_overview)

↑ Back to Top

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

Charles Schwab & Co., Inc., and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC (<https://www.sipc.org>)) ("Schwab"). Schwab Intelligent Portfolios® and Schwab Intelligent Portfolios Premium™ are made available through Charles Schwab & Co., Inc. ("Schwab"), a dually registered investment advisor and management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"). Schwab and CSIA are subsidiaries of



Bank's Show Indices
Symbol Lookup

DJIA ([https://client.schwab.com/secure/cc/nngw/wsod?path=/retail/research/markets/chart&symbol=\\$DJI](https://client.schwab.com/secure/cc/nngw/wsod?path=/retail/research/markets/chart&symbol=$DJI))
23,650.44 -592.05 (-2.44%)

<https://client.schwab.com/Apps/accounts/transactionhistory/#!/>

102

<https://client.schwab.com/secure/cc/accounts>[Messages](#)[Contact Us](#)[Help](#)[Accounts \(https://client.schwab.com/secure/cc/accounts\)](https://client.schwab.com/secure/cc/accounts)[Trade \(https://client.schwab.com/secure/cc/trade\)](https://client.schwab.com/secure/cc/trade)[Research \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Products \(https://client.schwab.com/secure/cc/products\)](https://client.schwab.com/secure/cc/products)[Specialty \(https://client.schwab.com/secure/cc/guidance\)](https://client.schwab.com/secure/cc/guidance)[Service \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Summary \(https://client.schwab.com/secure/cc/accounts/summary\)](https://client.schwab.com/secure/cc/accounts/summary)[Balances \(https://client.schwab.com/secure/cc/accounts/balances\)](https://client.schwab.com/secure/cc/accounts/balances)[Positions \(https://client.schwab.com/secure/cc/accounts/positions\)](https://client.schwab.com/secure/cc/accounts/positions)[History \(https://client.schwab.com/secure/cc/accounts/historynew\)](https://client.schwab.com/secure/cc/accounts/historynew)[Statements \(https://client.schwab.com/secure/cc/accounts/statementshistory\)](https://client.schwab.com/secure/cc/accounts/statementshistory)[Transfers & Payments \(https://client.schwab.com/secure/cc/accounts/transfers_and_payment\)](https://client.schwab.com/secure/cc/accounts/transfers_and_payment)Page last updated: 05:27 PM ET, 04/20/2020 [Refresh](#) [Export](#) [Print](#)

(b) (6)



IRA Contributory
Transactions 2019

Transactions From 01/01/2019 To 12/31/2019

Date ▼	Action	Details	Symbol	Description*	Quantity	Price	Fees & Comm	Amount
12/30/2019	Cash Dividend		AWIX	CIBC ATLAS INCM OPPTY FD INST				\$394.67
12/30/2019	Reinvest Dividend		AWEIX	CIBC ATLAS DISCIPLINED EQTY FD INST				\$1,462.70
12/30/2019	Reinvest Shares		AWEIX	CIBC ATLAS DISCIPLINED EQTY FD INST				-\$1,462.70
12/20/2019	Cash Dividend		HIEMX	VIRTUS VONTOBEL EMRG MKTS OPPTY FD I				\$386.93
12/20/2019	Reinvest Shares		HIEMX	VIRTUS VONTOBEL EMRG MKTS OPPTY FD I				-\$47.02
12/20/2019	Reinvest Shares		HIEMX	VIRTUS VONTOBEL EMRG MKTS OPPTY FD I				-\$32.87
12/20/2019	Long Term Cap Gain Reinvest		HIEMX	VIRTUS VONTOBEL EMRG MKTS OPPTY FD I				\$47.02
12/20/2019	Short Term Cap Gain Reinvest		HIEMX	VIRTUS VONTOBEL EMRG MKTS OPPTY FD I				\$32.87
12/19/2019	Long Term Cap Gain		EGFIX	EDGEWOOD GROWTH INSTL				\$93.15
12/19/2019	Cash Dividend		FLMVX	JPMORGAN MID CAP VALUE L				\$1,980.04
12/19/2019	Long Term Cap Gain Reinvest		AWEIX	CIBC ATLAS DISCIPLINED EQTY FD INST				\$2,245.88
12/19/2019	Reinvest Shares		AWEIX	CIBC ATLAS DISCIPLINED EQTY FD INST				-\$2,245.88
12/17/2019	Cash Dividend		MIPTX	MATTHEWS PACIFIC TIGER FD INSTL				\$519.85
12/17/2019	Long Term Cap Gain Reinvest		MIPTX	MATTHEWS PACIFIC TIGER FD INSTL				\$2,244.56

(b) (6)

Show Indices
Symbol Lookup
[DJIA \(https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\\$DJII\)](https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=$DJII)
 23,650.44 -592.05 (-2.44%)

<https://client.schwab.com/Apps/accounts/transactionhistory/#/>

103

1/3

(b) (6)

12/12/2019	Cash Dividend	TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND		\$735.85
12/12/2019	Cash Dividend	MIEIX	MFS INSTL INTL EQUITY		\$373.76
12/12/2019	Long Term Cap Gain Reinvest	FLMVX	JPMORGAN MID CAP VALUE L		\$3,115.54
12/12/2019	Long Term Cap Gain Reinvest	MIEIX	MFS INSTL INTL EQUITY		\$140.73
12/12/2019	Short Term Cap Gain Reinvest	TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND		\$41.25
12/12/2019	Long Term Cap Gain Reinvest	TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND		\$89.09
12/12/2019	Reinvest Shares	FLMVX	JPMORGAN MID CAP VALUE L	(b) (6)	-\$3,115.54
12/12/2019	Reinvest Shares	MIEIX	MFS INSTL INTL EQUITY		-\$140.73
12/12/2019	Reinvest Shares	TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND		-\$89.09
12/12/2019	Reinvest Shares	TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND		-\$41.25
12/10/2019	Long Term Cap Gain Reinvest	EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I		\$475.01
12/10/2019	Reinvest Dividend	EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I		\$118.88
12/10/2019	Reinvest Shares	EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I		-\$475.01
12/10/2019	Reinvest Shares	EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I		-\$118.88
11/18/2019 as of 11/15/2019	Bank Interest			(b) (6)	
10/16/2019	Tax Withholding		DC STATE TAX W/H IRA7		-\$2,296.49
10/16/2019	Tax Withholding		FED INC TAX WHLD IRA7		-\$2,551.65
10/16/2019	Journal			(b) (6)	
10/16/2019 as of 10/15/2019	Bank Interest			(b) (6)	
10/10/2019	Sell	Trade Details	AWEIX	CIBC ATLAS DISCIPLINED EQTY FD INST	\$20,000.00
09/30/2019	Reinvest Dividend	EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I		\$153.93
09/30/2019	Reinvest Shares	EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I		-\$153.93
09/27/2019	Cash Dividend	AWIIX	CIBC ATLAS INCM OPTPT FD INST		\$280.92
09/16/2019 as of 09/15/2019	Bank Interest			(b) (6)	
08/16/2019 as of 08/15/2019	Bank Interest				
07/16/2019 as of 07/15/2019	Bank Interest				



OPEN THE BOOKS™
Every Day. Online. In Real Time.

Quote

Show Indices
Symbol Lookup

DJIA ([https://client.schwab.com/secure/cc/nn/gw/wsd?path=/retail/research/markets/chart/&symbol=\\$DJIA](https://client.schwab.com/secure/cc/nn/gw/wsd?path=/retail/research/markets/chart/&symbol=$DJIA))
23,650.44 -592.05 (-2.44%)

06/28/2019	Reinvest Dividend	NASDAQ (https://client.schwab.com/secure/cc/nn/gw/wso?path=/retail/research/markets/chart/&symbol=\$SPX)	MAINSTAY EPOCH GLOBAL EQUITY YIELD I	(b) (6)	\$330.10
06/28/2019	Reinvest Dividend	S&P 500 (https://client.schwab.com/secure/cc/nn/gw/wso?path=/retail/research/markets/chart/&symbol=\$SPX)	MAINSTAY EPOCH GLOBAL EQUITY YIELD I	(b) (6)	\$330.10
06/28/2019	Reinvest Dividend	Russell 2000 (https://client.schwab.com/secure/cc/nn/gw/wso?path=/retail/research/markets/chart/&symbol=\$RUS2000)	MAINSTAY EPOCH GLOBAL EQUITY YIELD I	(b) (6)	\$330.10
06/27/2019	Cash Dividend	AWIIX	CIBC ATLAS INCM OPPTY FD INST	(b) (6)	\$343.99
06/17/2019 as of 06/15/2019	Bank Interest			(b) (6)	
05/16/2019 as of 05/15/2019	Bank Interest			(b) (6)	
04/16/2019 as of 04/15/2019	Bank Interest			(b) (6)	
03/29/2019	Reinvest Dividend	EPSYX	MAINSTAY EPOCH GLOBAL EQUITY YIELD I	(b) (6)	\$259.75
03/29/2019	Reinvest Shares	EPSYX	MAINSTAY EPOCH GLOBAL EQUITY YIELD I	(b) (6)	-\$259.75
Transactions Total					(b) (6)

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institution(s) referenced on the Balances detail page, your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

Accounts (https://client.schwab.com/secure/cc/accounts) Trade (https://client.schwab.com/secure/cc/trade) Research (https://client.schwab.com/secure/cc/research)
Products (https://client.schwab.com/secure/cc/products) Specialty (https://client.schwab.com/secure/cc/guidance) Service (https://client.schwab.com/secure/cc/service)
Summary (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/accounts/balances) Positions (https://client.schwab.com/secure/cc/accounts/positions)
History (https://client.schwab.com/secure/cc/accounts/historynew) Statements (https://client.schwab.com/secure/cc/accounts/statements/history)
Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payments_overview)

↑ Back to Top

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

Charles Schwab & Co., Inc., and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) ("Schwab"), Schwab Intelligent Portfolios® and Schwab Intelligent Portfolios Premium™ are made available through Charles Schwab & Co., Inc. ("Schwab"), a dually registered investment advisor and broker dealer. Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"). Schwab and CSIA are subsidiaries of The Charles Schwab Corporation. Deposit and lending products and services are offered by Charles Schwab Bank, SSB, Member FDIC and an Equal Housing Lender ("Schwab Bank").

Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured, in aggregate, up to \$250,000 per Affiliated Bank, per depositor, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unswept or intra-day cash, net credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) are not deposits or obligations of the Affiliated Banks, are subject to investment risk, are not FDIC insured, may lose value, and are not Affiliated Bank-guaranteed. Charles Schwab & Co., Inc. and the Affiliated Banks are separate entities and are all affiliates of The Charles Schwab Corporation.

© 2020 Charles Schwab & Co., Inc. All rights reserved. Member SIPC (https://www.sipc.org). Unauthorized access is prohibited. Usage will be monitored.

Agreements (https://client.schwab.com/secure/cc/nn/legal/compliance/agreements) Privacy (https://client.schwab.com/secure/cc/nn/security/privacy)
SchwabSafe (https://client.schwab.com/secure/cc/nn/security/schwabsafe) USA Patriot Act (https://client.schwab.com/secure/cc/nn/legal/compliance/usa_patriot_act.html)
FDIC Insurance (https://client.schwab.com/secure/cc/nn/legal/compliance/fdic_insurance.html) SIPC® (https://client.schwab.com/secure/cc/nn/legal/compliance/sipc.html)
Site Map (https://client.schwab.com/secure/cc/nn/site-map) Site Help (https://client.schwab.com/secure/cc/help/schwab_com/page_features/help) Support Session Bank Client Complaint (https://client.schwab.com/secure/cc/nn/legal/compliance/consumer-complaint-notice.html)

Messages

Contact Us

Help

<https://client.schwab.com/secure/cc/accounts>[Accounts \(https://client.schwab.com/secure/cc/accounts\)](https://client.schwab.com/secure/cc/accounts)[Trade \(https://client.schwab.com/secure/cc/trade\)](https://client.schwab.com/secure/cc/trade)[Research \(https://client.schwab.com/secure/cc/research\)](https://client.schwab.com/secure/cc/research)[Products \(https://client.schwab.com/secure/cc/products\)](https://client.schwab.com/secure/cc/products)[Specialty \(https://client.schwab.com/secure/cc/guidance\)](https://client.schwab.com/secure/cc/guidance)[Service \(https://client.schwab.com/secure/cc/service\)](https://client.schwab.com/secure/cc/service)[Summary \(https://client.schwab.com/secure/cc/accounts/summary\)](https://client.schwab.com/secure/cc/accounts/summary)[Balances \(https://client.schwab.com/secure/cc/accounts/balances\)](https://client.schwab.com/secure/cc/accounts/balances)[Positions \(https://client.schwab.com/secure/cc/accounts/positions\)](https://client.schwab.com/secure/cc/accounts/positions)[History \(https://client.schwab.com/secure/cc/accounts/historynew\)](https://client.schwab.com/secure/cc/accounts/historynew)[Statements \(https://client.schwab.com/secure/cc/accounts/statementshistory\)](https://client.schwab.com/secure/cc/accounts/statementshistory)[Transfers & Payments \(https://client.schwab.com/secure/cc/accounts/transfers_and_payment\)](https://client.schwab.com/secure/cc/accounts/transfers_and_payment)Page last updated: 05:27 PM ET, 04/20/2020 [Refresh](#) [Export](#) [Print](#)

Transactions From 01/01/2019 To 12/31/2019

Date ▼	Action	Details	Symbol	Description*	Quantity	Price	Fees & Comm	Amount
03/28/2019	Cash Dividend		AWIX	CIBC ATLAS INCM OPPTY FD INST				\$288.61
03/18/2019 as of 03/15/2019	Bank Interest							(b) (6)
02/19/2019 as of 02/15/2019	Bank Interest							
02/08/2019	Sell	Trade Details	TBGVX	TWEEDY BROWNE GLOBAL VALUE FUND			(b) (6)	\$74,985.00
02/08/2019	Buy	Trade Details	MIPTX	MATTHEWS PACIFIC TIGER FD INSTL				-\$75,015.00
01/16/2019 as of 01/15/2019	Bank Interest							(b) (6)

Transactions Total

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institution(s) referenced on the Balances detail page, your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

[Accounts \(https://client.schwab.com/secure/cc/accounts\)](https://client.schwab.com/secure/cc/accounts) [Trade \(https://client.schwab.com/secure/cc/trade\)](https://client.schwab.com/secure/cc/trade) [Research \(https://client.schwab.com/secure/cc/research\)](https://client.schwab.com/secure/cc/research) [Products \(https://client.schwab.com/secure/cc/products\)](https://client.schwab.com/secure/cc/products) [Specialty \(https://client.schwab.com/secure/cc/guidance\)](https://client.schwab.com/secure/cc/guidance) [Service \(https://client.schwab.com/secure/cc/service\)](https://client.schwab.com/secure/cc/service) [Summary \(https://client.schwab.com/secure/cc/accounts/summary\)](https://client.schwab.com/secure/cc/accounts/summary) [Balances \(https://client.schwab.com/secure/cc/accounts/balances\)](https://client.schwab.com/secure/cc/accounts/balances) [Positions \(https://client.schwab.com/secure/cc/accounts/positions\)](https://client.schwab.com/secure/cc/accounts/positions) [History \(https://client.schwab.com/secure/cc/accounts/historynew\)](https://client.schwab.com/secure/cc/accounts/historynew) [Statements \(https://client.schwab.com/secure/cc/accounts/statementshistory\)](https://client.schwab.com/secure/cc/accounts/statementshistory) [Transfers & Payments \(https://client.schwab.com/secure/cc/accounts/transfers_and_payment\)](https://client.schwab.com/secure/cc/accounts/transfers_and_payment)

[Back to Top](#)

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

Charles Schwab & Co., Inc., and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) ("Schwab"), Schwab Intelligent Portfolios[®] and Schwab Intelligent Portfolios Premium[™] are made available through Charles Schwab & Co., Inc. ("Schwab"), a dually registered investment advisor and broker dealer. Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSI/A"). Schwab and CSI/A are subsidiaries of The Charles Schwab Corporation. Deposit and lending products and services are offered by Charles Schwab Bank, SSB, Member FDIC and an Equal Housing Lender ("Schwab Bank").

Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured, in aggregate, up to \$250,000 per Affiliated Bank, per depositor, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unswept or intra-day cash, net credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) are not deposits or obligations of the Affiliated Banks, are subject to FDIC insured, may lose value, and are not Affiliated Bank-guaranteed. Charles Schwab & Co., Inc. and the Affiliated Banks are



For a list of the Charles Schwab Corporation's
Show Indices
etc., log on to <https://www.schwab.com>

DJIA (https://client.schwab.com/secure/cc/nn/gw/wso?path=/retail/research/markets/chart&symbol=\$DJIA)
etc., log on to <https://www.schwab.com> (https://www.sipc.org). Unauthorized access is prohibited. Usage will be monitored.

Messages

Contact Us

Help

<https://client.schwab.com/secure/cc/accounts>[Accounts \(https://client.schwab.com/secure/cc/accounts\)](https://client.schwab.com/secure/cc/accounts)[Trade \(https://client.schwab.com/secure/cc/trade\)](https://client.schwab.com/secure/cc/trade)[Research \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Products \(https://client.schwab.com/secure/cc/products\)](https://client.schwab.com/secure/cc/products)[Specialty \(https://client.schwab.com/secure/cc/guidance\)](https://client.schwab.com/secure/cc/guidance)[Service \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Summary \(https://client.schwab.com/secure/cc/accounts/summary\)](https://client.schwab.com/secure/cc/accounts/summary)[Balances \(https://client.schwab.com/secure/cc/accounts/balances\)](https://client.schwab.com/secure/cc/accounts/balances)[Positions \(https://client.schwab.com/secure/cc/accounts/positions\)](https://client.schwab.com/secure/cc/accounts/positions)[History \(https://client.schwab.com/secure/cc/accounts/historynew\)](https://client.schwab.com/secure/cc/accounts/historynew)[Statements \(https://client.schwab.com/secure/cc/accounts/statementshistory\)](https://client.schwab.com/secure/cc/accounts/statementshistory)[Transfers & Payments \(https://client.schwab.com/secure/cc/accounts/transfers_and_payment\)](https://client.schwab.com/secure/cc/accounts/transfers_and_payment)Page last updated: 04:18 PM ET, 04/30/2020  Refresh Export  Print

(b) (6)

Revocable Trust
Transactions - 2019

Transactions From 01/01/2019 To 12/31/2019

Date ▼	Action	Details	Symbol	Description*	Quantity	Price	Fees & Comm	Amount
12/31/2019	Cash Dividend		PRSMX	T ROWE PRICE SUMMIT MUNI INTERM INV				\$1,896.46
12/31/2019	Cash Dividend		FIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST				\$1,217.61
12/31/2019	Cash Dividend		SWGXX	SCHWAB GOVT MONEY FUND				
12/31/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				-\$11,969.93
12/30/2019	Cash Dividend		AWIIX	CIBC ATLAS INCM OPPTY FD INST				\$2,159.43
12/30/2019	Cash Dividend		AWEIX	CIBC ATLAS DISCIPLINED EQTY FD INST				\$9,810.60
12/24/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				\$249,446.06
12/23/2019	Cash Dividend		VSMAX	VANGUARD SMALL CAP INDEX ADMIRAL SHARE				\$583.95
12/23/2019	Buy	Trade Details	MIEIX	MFS INSTL INTL EQUITY				-\$209,015.00
12/23/2019	Buy	Trade Details	EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I				-\$50,015.00
12/20/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				-\$2,667.81
12/19/2019	Cash Dividend		FLMVX	JPMORGAN MID CAP VALUE L				\$2,867.81
12/19/2019	Long Term Cap Gain Reinvest		AWEIX	CIBC ATLAS DISCIPLINED EQTY FD INST				\$15,063.42
12/19/2019	Reinvest Shares		AWEIX	CIBC ATLAS DISCIPLINED EQTY FD INST				-\$15,063.42

(b) (6)



Show Indices
Symbol Lookup

DJIA ([https://client.schwab.com/secure/cc/nn/gw/wsod?path=/research/markets/chart/&symbol=\\$DJIA](https://client.schwab.com/secure/cc/nn/gw/wsod?path=/research/markets/chart/&symbol=$DJIA))
24,345.72 -288.14 (-1.17%)

<https://client.schwab.com/Apps/accounts/transactionhistory/#/>

(b) (6) (1)-(5)(C)

(b) (6)

(b) (6)

11/01/2019	Buy	NASDAQ (https://client.schwab.com/secure/cc/nn/gw/wso?path=/retail/research/markets/chart&symbol=\$SPX)	8,689.55 -28.16 (-0.28%)	EMRG MKTS CL I	-\$75,015.00
		S&P 500 (https://client.schwab.com/secure/cc/nn/gw/wso?path=/retail/research/markets/chart&symbol=\$SPX)	2,912.43 -27.08 (-0.92%)		
		Russian (https://client.schwab.com/secure/cc/nn/gw/wso?path=/retail/research/markets/chart&symbol=RUSS)	1,310.66 -50.10 (-3.68%)		-\$50,015.00
11/01/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	-\$3,090.60
10/31/2019	Cash Dividend		PRSMX	T ROWE PRICE SUMMIT MUNI INTERM INV	\$1,911.48
10/31/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST	\$1,179.32
10/17/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	-\$20,668.39
10/16/2019	Journal			(b) (4), (b) (6)	\$20,668.39
10/16/2019 as of 10/15/2019	Cash Dividend		SWGXX	SCHWAB GOVT MONEY FUND	(b) (6)

Transactions Total

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institution(s) referenced on the Balances detail page, your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

Accounts (https://client.schwab.com/secure/cc/accounts) Trade (https://client.schwab.com/secure/cc/trade) Research (https://client.schwab.com/secure/cc/research) Products (https://client.schwab.com/secure/cc/products) Specialty (https://client.schwab.com/secure/cc/guidance) Service (https://client.schwab.com/secure/cc/service) Summary (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/accounts/balances) Positions (https://client.schwab.com/secure/cc/accounts/positions) History (https://client.schwab.com/secure/cc/accounts/historynew) Statements (https://client.schwab.com/secure/cc/accounts/statements/history) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payments_overview)

↑ Back to Top

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

Charles Schwab & Co., Inc., and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) ("Schwab"). Schwab Intelligent Portfolios® and Schwab Intelligent Portfolios Premium™ are made available through Charles Schwab & Co., Inc. ("Schwab"), a dually registered investment advisor and broker dealer. Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"). Schwab and CSIA are subsidiaries of The Charles Schwab Corporation. Deposit and lending products and services are offered by Charles Schwab Bank, SSB. Member FDIC and an Equal Housing Lender ("Schwab Bank").

Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured, in aggregate, up to \$250,000 per Affiliated Bank, per depositor, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unswept or intra-day cash, net credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) are not deposits or obligations of the Affiliated Banks, are subject to investment risk, are not FDIC insured, may lose value, and are not Affiliated Bank-guaranteed. Charles Schwab & Co., Inc. and the Affiliated Banks are separate entities and are all affiliates of The Charles Schwab Corporation.

© 2020 Charles Schwab & Co., Inc. All rights reserved. Member SIPC (https://www.sipc.org). Unauthorized access is prohibited. Usage will be monitored.




Agreements (https://client.schwab.com/secure/cc/nn/legal_compliance/agreements) Privacy (https://client.schwab.com/secure/cc/nn/security/privacy) SchwabSafe (https://client.schwab.com/secure/cc/nn/security/schwabsafe) USA Patriot Act (https://client.schwab.com/secure/cc/nn/legal_compliance/usa_patriot_act.cfm) SIPC® (https://client.schwab.com/secure/cc/nn/legal_compliance/sipc.html) FDIC Insurance (https://client.schwab.com/secure/cc/nn/legal_compliance/fdic_insurance.html) Site Map (https://client.schwab.com/secure/cc/nn/sitemap) Site Help (https://client.schwab.com/secure/cc/help/schwab_com/page_features/help) Support Session: Bank Client Complaint (/secure/cc/nn/legal_compliance/consumer-complaint-notice.html)

<https://client.schwab.com/secure/cc/accounts>

Messages

Contact Us

Help

[Accounts \(https://client.schwab.com/secure/cc/accounts\)](https://client.schwab.com/secure/cc/accounts)[Trade \(https://client.schwab.com/secure/cc/trade\)](https://client.schwab.com/secure/cc/trade)[Research \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Products \(https://client.schwab.com/secure/cc/products\)](https://client.schwab.com/secure/cc/products)[Specialty \(https://client.schwab.com/secure/cc/guidance\)](https://client.schwab.com/secure/cc/guidance)[Service \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Summary \(https://client.schwab.com/secure/cc/accounts/summary\)](https://client.schwab.com/secure/cc/accounts/summary)[Balances \(https://client.schwab.com/secure/cc/accounts/balances\)](https://client.schwab.com/secure/cc/accounts/balances)[Positions \(https://client.schwab.com/secure/cc/accounts/positions\)](https://client.schwab.com/secure/cc/accounts/positions)[History \(https://client.schwab.com/secure/cc/accounts/historynew\)](https://client.schwab.com/secure/cc/accounts/historynew)[Statements \(https://client.schwab.com/secure/cc/accounts/statementshistory\)](https://client.schwab.com/secure/cc/accounts/statementshistory)[Transfers & Payments \(https://client.schwab.com/secure/cc/accounts/transfers_and_payment\)](https://client.schwab.com/secure/cc/accounts/transfers_and_payment)Page last updated: 04:18 PM ET, 04/30/2020  Refresh  Export  Print

Transactions From 01/01/2019 To 12/31/2019

Date ▼	Action	Details	Symbol	Description*	Quantity	Price	Fees & Comm	Amount
10/11/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	(b) (6)			-\$1,069.77
10/10/2019	Cash Dividend		VMIX	VERSUS CAP MULTI MGR REAL ESTATE INCM FD INST				\$1,060.77
10/01/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				-\$3,146.44
09/30/2019	Cash Dividend		PRSMX	T ROWE PRICE SUMMIT MUNI INTERM INV				\$1,731.78
09/30/2019	Cash Dividend		PICIX	PIMCO INVESTMENT GRADE CREDIT BD INST				\$1,090.46
09/30/2019	Cash Dividend		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I				\$324.20
09/30/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				-\$1,464.72
09/27/2019	Cash Dividend		AWIIX	CIBC ATLAS INCM OPPTY FD INST				\$1,464.72
09/17/2019 as of 09/16/2019	Cash Dividend		SWGXX	SCHWAB GOVT MONEY FUND				
09/16/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				-\$294.16
09/13/2019	Cash Dividend		VSMAX	VANGUARD SMALL CAP INDEX ADMIRAL SHARE				\$294.16
09/10/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				-\$6,240.00
09/09/2019	Journal			(b) (4), (b) (6)				\$3,080.00
09/09/2019	Journal							\$3,160.00

Show Indices
Symbol Lookup
[DJIA \(https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart&symbol=\\$DJ1\)](https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart&symbol=$DJ1)
 24,345.72 -288.14 (-1.17%)

4/30/2020

Charles Schwab Client Center

09/03/2019	Buy		SWGXX	SCHWAB GOVT MONEY FUND	(b) (6)	-\$3,280.54
S&P 500 (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\$SPX) 2,912.43 -27.08 (-0.92%)						
Russell 2000 (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\$RUS2000) 1,310.66 -50.10 (-3.68%)						
08/30/2019	Cash Dividend	PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST			\$1,236.60
08/29/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$75,000.00
08/28/2019	Funds Received	Deposit Details		FUNDS RECEIVED		\$75,000.00
08/16/2019 as of 08/15/2019	Cash Dividend	SWGXX	SCHWAB GOVT MONEY FUND			
08/13/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		\$5,561.34
08/12/2019	Advisor Fee				(b) (6)	
08/09/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	(b) (6)	-\$865.12
08/06/2019	Cash Dividend	VCRRX	VERSUS CAP REAL ASSET FUND			\$865.12
08/05/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		\$200,060.00
08/02/2019	Buy	Trade Details	AWMIX	CIBC ATLAS MID CAP EQTY FD INST		-\$50,015.00
08/02/2019	Buy	Trade Details	PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST		-\$50,015.00
08/02/2019	Buy	Trade Details	FLMVX	JPMORGAN MID CAP VALUE L		-\$25,015.00
08/02/2019	Buy	Trade Details	AWEIX	CIBC ATLAS DISCIPLINED EQTY FD INST		-\$25,015.00
08/02/2019	Buy	Trade Details	PRSMX	T ROWE PRICE SUMMIT MUNI INTERM INV		-\$50,000.00
08/01/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$2,859.99
07/31/2019	Cash Dividend	PRSMX	T ROWE PRICE SUMMIT MUNI INTERM INV			\$1,844.01
07/31/2019	Cash Dividend	PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST			\$1,015.98
07/26/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$100,000.00
07/24/2019	Funds Received	Deposit Details		FUNDS RECEIVED		\$100,000.00
07/16/2019 as of 07/15/2019	Cash Dividend	SWGXX	SCHWAB GOVT MONEY FUND			
07/12/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$1,078.75
07/11/2019	Cash Dividend	VCMIX	VERSUS CAP MULTI MNGR REAL ESTATE INCM FD INST			\$1,078.75
07/01/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$3,370.04
06/28/2019	Cash Dividend	PRSMX	T ROWE PRICE SUMMIT MUNI INTERM INV			\$1,692.85
06/28/2019	Cash Dividend	PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST			\$972.70
06/28/2019	Cash Dividend	EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I			\$704.49



Show Indices
Symbol Lookup

DJIA (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\$DJIA) 24,345.72 -288.14 (-1.17%)

https://client.schwab.com/Apps/accounts/transactionhistory/##

06/28/2019	Buy	NASDAQ (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\$SPX)	8,589.35 -25.16 (-0.28%)	SCHWAB GOVT MONEY FUND	-\$1,931.10
06/27/2019	Cash Dividend	S&P 500 (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\$SPX)	2,912.43 -27.08 (-0.92%)	VANGUARD SMALL CAP INDEX ADMIRAL SHARE	\$1,931.10
06/27/2019	Cash Dividend	Russell 2000 (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart/&symbol=\$RUS2)	1,310.66 -50.10 (-3.68%)	SCHWAB GOVT MONEY FUND	-\$318.95
06/27/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	-\$6,240.00
06/26/2019	Cash Dividend		VSMAX	VANGUARD SMALL CAP INDEX ADMIRAL SHARE	\$3,080.00
06/18/2019 as of 06/17/2019	Cash Dividend		SWGXX	SCHWAB GOVT MONEY FUND	\$3,160.00
06/11/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	
06/10/2019	Journal				
05/10/2019	Journal				

Transactions Total

(b) (6)

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institution(s) referenced on the Balances detail page, your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

Accounts (https://client.schwab.com/secure/cc/accounts) Trade (https://client.schwab.com/secure/cc/trade) Research (https://client.schwab.com/secure/cc/research) Products (https://client.schwab.com/secure/cc/products) Specialty (https://client.schwab.com/secure/cc/guidance) Service (https://client.schwab.com/secure/cc/service) Summary (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/accounts/balances) Positions (https://client.schwab.com/secure/cc/accounts/positions) History (https://client.schwab.com/secure/cc/accounts/historynew) Statements (https://client.schwab.com/secure/cc/accounts/statements/history) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payments/overview)

↑ Back to Top

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

(b) (6)

Charles Schwab & Co., Inc., and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) ("Schwab"). Schwab Intelligent Portfolios® and Schwab Intelligent Portfolios Premium™ are made available through Charles Schwab & Co., Inc. ("Schwab"), a dually registered investment advisor and broker-dealer. Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"). Schwab and CSIA are subsidiaries of The Charles Schwab Corporation. Deposit and lending products and services are offered by Charles Schwab Bank, SSB, Member FDIC and an Equal Housing Lender ("Schwab Bank").

Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured, in aggregate, up to \$250,000 per Affiliated Bank, per depositor, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unswept or intra-day cash, net credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) are not deposits or obligations of the Affiliated Banks, are subject to investment risk, are not FDIC insured, may lose value, and are not Affiliated Bank-guaranteed. Charles Schwab & Co., Inc. and the Affiliated Banks are separate entities and are all affiliates of The Charles Schwab Corporation.

© 2020 Charles Schwab & Co., Inc. All rights reserved. Member SIPC (https://www.sipc.org). Unauthorized access is prohibited. Usage will be monitored.

Agreements (https://client.schwab.com/secure/cc/nn/legal/compliance/agreements) Privacy (https://client.schwab.com/secure/cc/nn/security/privacy) SchwabSafe (https://client.schwab.com/secure/cc/nn/security/schwabsafe) USA Patriot Act (https://client.schwab.com/secure/cc/nn/legal/compliance/usa_patriot_act.html) SIPC® (https://client.schwab.com/secure/cc/nn/legal/compliance/sipc.html) FDIC Insurance (https://client.schwab.com/secure/cc/nn/legal/compliance/fdic_insurance.html) Site Map (https://client.schwab.com/secure/cc/nn/sitemap) Site Help (https://client.schwab.com/secure/cc/help/schwab_com/page/features/help) Support Session Bank Client Complaint (https://client.schwab.com/secure/cc/nn/legal/compliance/consumer-complaint-notice.html)






<https://client.schwab.com/secure/cc/accounts>

Messages

Contact Us

Help

[Accounts \(https://client.schwab.com/secure/cc/accounts\)](https://client.schwab.com/secure/cc/accounts)[Trade \(https://client.schwab.com/secure/cc/trade\)](https://client.schwab.com/secure/cc/trade)[Research \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Products \(https://client.schwab.com/secure/cc/products\)](https://client.schwab.com/secure/cc/products)[Specialty \(https://client.schwab.com/secure/cc/guidance\)](https://client.schwab.com/secure/cc/guidance)[Service \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Summary \(https://client.schwab.com/secure/cc/accounts/summary\)](https://client.schwab.com/secure/cc/accounts/summary)[Balances \(https://client.schwab.com/secure/cc/accounts/balances\)](https://client.schwab.com/secure/cc/accounts/balances)[Positions \(https://client.schwab.com/secure/cc/accounts/positions\)](https://client.schwab.com/secure/cc/accounts/positions)[History \(https://client.schwab.com/secure/cc/accounts/historynew\)](https://client.schwab.com/secure/cc/accounts/historynew)[Statements \(https://client.schwab.com/secure/cc/accounts/statementshistory\)](https://client.schwab.com/secure/cc/accounts/statementshistory)[Transfers & Payments \(https://client.schwab.com/secure/cc/accounts/transfers_and_payment\)](https://client.schwab.com/secure/cc/accounts/transfers_and_payment)Page last updated: 04:18 PM ET, 04/30/2020  Refresh  Export  Print

Transactions From 01/01/2019 To 12/31/2019

Date ▼	Action	Details	Symbol	Description*	Quantity	Price	Fees & Comm	Amount
06/03/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	(b) (6)			-\$2,974.59
05/31/2019	Cash Dividend		PRSMX	T ROWE PRICE SUMMIT MUNI INTERM INV				\$1,859.65
05/31/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST				\$1,104.94
05/20/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				\$100,015.00
05/17/2019	Buy	Trade Details	VSMAX	VANGUARD SMALL CAP INDEX ADMIRAL SHARE				-\$100,015.00
05/17/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				\$100,000.00
05/16/2019	Buy	Trade Details	PRSMX	T ROWE PRICE SUMMIT MUNI INTERM INV				-\$100,000.00
05/16/2019 as of 05/15/2019	Cash Dividend		SWGXX	SCHWAB GOVT MONEY FUND				
05/14/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				\$5,042.62
05/13/2019	Advisor Fee							(b) (6)
05/10/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	(b) (6)			-\$804.44
05/09/2019	Cash Dividend		VCRRX	VERSUS CAP REAL ASSET FUND				\$804.44
05/09/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				-\$300,000.00
05/08/2019	Funds Received	Deposit Details		FUNDS RECEIVED				\$300,000.00

Show Indices
Symbol Lookup
[DJIA \(https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart&symbol=\\$DJIA\)](https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart&symbol=$DJIA)
24,345.72 -288.14 (-1.17%)
<https://client.schwab.com/Apps/accounts/transactionhistory/#/>

4/30/2020

Charles Schwab Client Center

05/01/2019	Buy	NASDAQ (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart&symbol=SWGXX)	SWGXX	SCHWAB GOVT MONEY FUND	(b) (6)	-\$2,597.04
S&P 500 (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart&symbol=SPX)						
2,912.43 -27.08 (-0.92%)						
04/30/2019	Cash Dividend	Russell 2000 (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart&symbol=RSX)	RSX	T ROWE PRICE SUMMIT MUNI INTERM INV		\$1,673.21
1,310.66 -50.10 (-3.68%)						
04/30/2019	Cash Dividend	PIGIX	PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST		\$1,023.83
04/29/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		\$4,395.47
04/24/2019	Buy	Trade Details	HLMEH	HARDING LOEVNER INST EMRG MKTS CL I		-\$25,015.00
04/24/2019	Sell	Trade Details	IMQX	IVA INTL FD CL I		\$45,634.53
04/24/2019	Buy	Trade Details	MIPTX	MATTHEWS PACIFIC TIGER FD INSTL		-\$25,015.00
04/18/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$2,281.00
04/17/2019	Journal			(b) (4), (b) (6)		\$2,281.00
04/17/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$8,433.00
04/16/2019	Journal			(b) (4), (b) (6)		\$8,433.00
04/16/2019 as of 04/15/2019	Cash Dividend		SWGXX	SCHWAB GOVT MONEY FUND		
04/16/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		\$28,886.29
04/15/2019	Cash Dividend		VCMIH	VERSUS CAP MULTI MNGR REAL ESTATE INCM FD INST		\$1,114.71
04/15/2019	Journal			(b) (4), (b) (6)		-\$100,000.00
04/12/2019	Sell	Trade Details	PRSMX	T ROWE PRICE SUMMIT MUNI INTERM FUND INV		\$70,000.00
04/03/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$3,407.00
03/29/2019	Cash Dividend		PRSMX	T ROWE PRICE SUMMIT MUNI INTERM FUND INV		\$1,799.60
03/29/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST		\$1,047.20
03/29/2019	Cash Dividend		EPSYX	MAINSTAY EPOCH GLOBAL EQTY YIELD I		\$580.20
03/29/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$1,620.18
03/28/2019	Cash Dividend		AWIIX	CIBC ATLAS INCM OPPTY FD INST		\$1,620.18
03/18/2019 as of 03/15/2019	Cash Dividend		SWGXX	SCHWAB GOVT MONEY FUND		
03/01/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		-\$2,520.00
02/28/2019	Cash Dividend		PRSMX	T ROWE PRICE SUMMIT MUNI INTERM FUND INV		\$1,640.99
02/28/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST		\$979.01
02/19/2019 as of 02/15/2019	Cash Dividend		SWGXX	SCHWAB GOVT MONEY FUND		
02/12/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND		\$3,878.01



OPEN THE BOOKS
Every Day. Online. In Real Time.

Show Indices
Symbol Lookup

DJIA (https://client.schwab.com/secure/cc/nn/gw/wsod?path=/retail/research/markets/chart&symbol=\$DJIA)
24,345.72 -268.14 (-1.17%)

https://client.schwab.com/Apps/accounts/transactionhistory/#/

02/11/2019	Cash Dividend	NASDAQ (https://client.schwab.com/secure/cc/nn/gw/wsood?path=/retail/research/markets/chart/&symbol=NASDAQ)	VERSUS CAP REAL ASSE		\$865.12
02/11/2019		S&P 500 (https://client.schwab.com/secure/cc/nn/gw/wsood?path=/retail/research/markets/chart/&symbol=\$SP)	FUND		
02/11/2019		Russ 2000 (https://client.schwab.com/secure/cc/nn/gw/wsood?path=/retail/research/markets/chart/&symbol=RUS2000)	TO ADMSCF		-\$4,743.13
02/11/2019	Sell	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	\$49,891.77
02/08/2019	Sell	Trade Details	MIEIX	MFS INSTL INTL EQUITY	\$123.23
02/08/2019	Buy	Trade Details	MPTX	MATTHEWS PACIFIC TIGER FD INSTL	-\$50,015.00
02/01/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	-\$2,716.06
01/31/2019	Cash Dividend		PRSMX	T ROWE PRICE SUMMIT MUNI INTERM FUND INV	\$1,763.32
01/31/2019	Cash Dividend		PIGIX	PIMCO INVESTMENT GRADE CREDIT BD INST	\$952.74

Transactions Total

*Transactions may include Bank Sweep deposit information. Bank Sweep deposits are held at the FDIC-insured depository institution(s) referenced on the Balances detail page, your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

(b) (6)

Accounts (https://client.schwab.com/secure/cc/accounts) Trade (https://client.schwab.com/secure/cc/trade) Research (https://client.schwab.com/secure/cc/research) Products (https://client.schwab.com/secure/cc/products) Specialty (https://client.schwab.com/secure/cc/guidance) Service (https://client.schwab.com/secure/cc/service) Summary (https://client.schwab.com/secure/cc/accounts/summary) Balances (https://client.schwab.com/secure/cc/accounts/balances) Positions (https://client.schwab.com/secure/cc/accounts/positions) History (https://client.schwab.com/secure/cc/accounts/historynew) Statements (https://client.schwab.com/secure/cc/accounts/statements/history) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payments_overview)

↑ Back to Top

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

Charles Schwab & Co., Inc., and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) ("Schwab"). Schwab Intelligent Portfolios® and Schwab Intelligent Portfolios Premium™ are made available through Charles Schwab & Co., Inc. ("Schwab"), a dually registered investment advisor and broker dealer. Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"). Schwab and CSIA are subsidiaries of The Charles Schwab Corporation. Deposit and lending products and services are offered by Charles Schwab Bank, SSB, Member FDIC and an Equal Housing Lender ("Schwab Bank").

Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured, in aggregate, up to \$250,000 per Affiliated Bank, per depositor, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unswept or intra-day cash, net credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC (https://www.sipc.org)) are not deposits or obligations of the Affiliated Banks, are subject to investment risk, are not FDIC insured, may lose value, and are not Affiliated Bank-guaranteed. Charles Schwab & Co., Inc. and the Affiliated Banks are separate entities and are all affiliates of The Charles Schwab Corporation.

© 2020 Charles Schwab & Co., Inc. All rights reserved. Member SIPC (https://www.sipc.org). Unauthorized access is prohibited. Usage will be monitored.

Agreements (https://client.schwab.com/secure/cc/nn/legal_compliance/agreements) Privacy (https://client.schwab.com/secure/cc/nn/security/privacy) SchwabSafe (https://client.schwab.com/secure/cc/nn/security/schwabsafe) USA Patriot Act (https://client.schwab.com/secure/cc/nn/legal_compliance/usa_patriot_act.html) SIPC® (https://client.schwab.com/secure/cc/nn/legal_compliance/sipc.html) FDIC Insurance (https://client.schwab.com/secure/cc/nn/legal_compliance/fdic_insurance.html) Site Map (https://client.schwab.com/secure/cc/nn/sitemap) Site Help (https://client.schwab.com/secure/cc/help/schwab_com/page_features/help) Support Session Bank Client Complaint (https://client.schwab.com/secure/cc/nn/legal_compliance/consumer-complaint-notice.html)



Show Indices
Symbol Lookup

DJIA (https://client.schwab.com/secure/cc/nn/gw/wsood?path=/retail/research/markets/chart/&symbol=\$DJI)
24,345.72 -288.14 (-1.17%)

<https://client.schwab.com/secure/cc/accounts>[Messages](#)[Contact Us](#)[Help](#)[Accounts \(https://client.schwab.com/secure/cc/accounts\)](https://client.schwab.com/secure/cc/accounts)[Trade \(https://client.schwab.com/secure/cc/trade\)](https://client.schwab.com/secure/cc/trade)[Research \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Products \(https://client.schwab.com/secure/cc/products\)](https://client.schwab.com/secure/cc/products)[Specialty \(https://client.schwab.com/secure/cc/guidance\)](https://client.schwab.com/secure/cc/guidance)[Service \(https://client.schwab.com/secure/](https://client.schwab.com/secure/)[Summary \(https://client.schwab.com/secure/cc/accounts/summary\)](https://client.schwab.com/secure/cc/accounts/summary)[Balances \(https://client.schwab.com/secure/cc/accounts/balances\)](https://client.schwab.com/secure/cc/accounts/balances)[Positions \(https://client.schwab.com/secure/cc/accounts/positions\)](https://client.schwab.com/secure/cc/accounts/positions)[History \(https://client.schwab.com/secure/cc/accounts/historynew\)](https://client.schwab.com/secure/cc/accounts/historynew)[Statements \(https://client.schwab.com/secure/cc/accounts/statementshistory\)](https://client.schwab.com/secure/cc/accounts/statementshistory)[Transfers & Payments \(https://client.schwab.com/secure/cc/accounts/transfers_and_payment\)](https://client.schwab.com/secure/cc/accounts/transfers_and_payment)Page last updated: 04:18 PM ET, 04/30/2020 [Refresh](#) [Export](#) [Print](#)

Transactions From 01/01/2019 To 12/31/2019

Date ▼	Action	Details	Symbol	Description*	Quantity	Price	Fees & Comm	Amount
01/16/2019 as of 01/15/2019	Cash Dividend		SWGXX	SCHWAB GOVT MONEY FUND				
01/15/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND				-\$1,114.71
01/14/2019	Cash Dividend		VCMIX	VERSUS CAP MULTI MNGR REAL ESTATE INCM FD INST				\$1,114.71
01/02/2019	Buy	Trade Details	SWGXX	SCHWAB GOVT MONEY FUND	2,699.8			-\$2,699.80

Transactions Total

(b) (6)

*Transactions may include Bank Sweep deposits. Information, Bank Sweep deposits are held at the FDIC-insured depository institution(s) referenced on the Balances detail page, your account statements and disclosed in your account documents. SIPC does not cover balances held in the Bank Sweep feature.

0007-7604

Accounts (<https://client.schwab.com/secure/cc/accounts>) Trade (<https://client.schwab.com/secure/cc/trade>) Research (<https://client.schwab.com/secure/cc/research>) Products (<https://client.schwab.com/secure/cc/products>) Specialty (<https://client.schwab.com/secure/cc/guidance>) Service (<https://client.schwab.com/secure/cc/service>) Summary (<https://client.schwab.com/secure/cc/accounts/summary>) Balances (<https://client.schwab.com/secure/cc/accounts/balances>) Positions (<https://client.schwab.com/secure/cc/accounts/positions>) History (<https://client.schwab.com/secure/cc/accounts/historynew>) Statements (<https://client.schwab.com/secure/cc/accounts/statementshistory>) Transfers & Payments (https://client.schwab.com/secure/cc/accounts/transfers_and_payments_overview)

[Back to Top](#)

Brokerage Products: Not FDIC Insured No Bank Guarantee May Lose Value

Charles Schwab & Co., Inc., and Charles Schwab Bank, SSB are separate but affiliated companies and subsidiaries of The Charles Schwab Corporation. Brokerage products are offered by Charles Schwab & Co., Inc. (Member SIPC (<https://www.sipc.org>)) ("Schwab"). Schwab Intelligent Portfolios® and Schwab Intelligent Portfolios Premium™ are made available through Charles Schwab & Co., Inc. ("Schwab"), a dually registered investment advisor and broker-dealer. Portfolio management services are provided by Charles Schwab Investment Advisory, Inc. ("CSIA"). Schwab and CSIA are subsidiaries of The Charles Schwab Corporation. Deposit and lending products and services are offered by Charles Schwab Bank, SSB, Member FDIC and an Equal Housing Lender ("Schwab Bank").

Bank Sweep deposits are held at one or more FDIC-insured banks that are affiliated with Charles Schwab & Co., Inc. ("Affiliated Banks"). Funds deposited at Affiliated Banks are insured, in aggregate, up to \$250,000 per Affiliated Bank, per depositor, for each account ownership category, by the Federal Deposit Insurance Corporation (FDIC). Securities products and services (including unswept or intra-day cash, net credit or debit balances, and money market funds) offered by Charles Schwab & Co., Inc. (Member SIPC (<https://www.sipc.org>)) are not deposits or obligations of the Affiliated Banks, are subject to investment risk, are not FDIC insured, may lose value, and are not Affiliated Bank-guaranteed. Charles Schwab & Co., Inc. and the Affiliated Banks are separate entities and are all affiliates of The Charles Schwab Corporation.

© 2020 Charles Schwab & Co., Inc. All rights reserved. Member SIPC (<https://www.sipc.org>). Unauthorized access is prohibited. Usage will be monitored.

Agreements (<https://client.schwab.com/secure/cc/legal/compliance/agreements>) Privacy (<https://client.schwab.com/secure/cc/legal/compliance/privacy>)
 SchwabSafe (<https://client.schwab.com/secure/cc/legal/compliance/schwabsafe>) USA Patriot Act (https://client.schwab.com/secure/cc/legal/compliance/usa_patriot_act.html)
 SIPC® (<https://client.schwab.com/secure/cc/legal/compliance/sipc.html>)
 FDIC Insurance (https://client.schwab.com/secure/cc/legal/compliance/fdic_insurance.html) Site Map (<https://client.schwab.com/secure/cc/legal/compliance/site-map>)
 Support Session Bank Claim Complaint (<https://client.schwab.com/secure/cc/legal/compliance/consumer-complaint-notice.html>)



Show Indices
Symbol Lookup

DJIA (<https://client.schwab.com/secure/cc/legal/compliance/djia>)
 24,345.72 -288.14 (-1.17%)

<https://client.schwab.com/Apps/accounts/transactionhistory/#/>